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 The archazolids are a complex family of natural products with distinct structural 
features. Inspired by these unique structural characteristics, our group sought to synthesize an 
analogue of this family, dihydroarchazolid B. We were encouraged to synthesize this 
analogue due to its high potential to be a potent cytotoxic agent against the vacuolar-type 
ATPases (V-ATPases) and because it is a simpler analogue than the parent natural products 
from a synthetic perspective. Within this work, a ring-closing metathesis (RCM) approach 
was explored in depth towards the completion of our target. From these efforts, a metathesis 
deactivating stereotriad was uncovered in a key fragment needed for ring closure. Using the 
knowledge uncovered in our synthetic endeavors, a possible relay-ring closure event is 
discussed.  The synthetic utility of exploring the effects of contiguous remote functionality 
on alkene reactivity is also demonstrated as knowledge of this type will better inform our 
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Chapter 1. Introduction  
1.1 Isolation and Structural Determination of the Archazolid Natural Products 
The archazolid family of natural products comprises six members (A-F) sharing 
distinct structural features (Figure 1-1). The unique architecture of the archazolids is 
characterized by a 24-membered macrolactone ring with a thiazole side chain, seven 
alkenes (2E,5E,9Z,11Z,13E,18E,20E), and a sequence of eight methyl- and hydroxyl-
bearing stereocenters.1 During a screening for new, biologically active metabolites in 
from myxobacteria in 1993, Sasse et al. found a strain of Archangium gephyra that 
showed high cytotoxic activity in a screening assay with L929 mouse fibroblasts. This 
activity was attributed to two new related compounds which they called archazolid A and 
B.2 The planar structures of A and B were elucidated by Höfle and Steinmetz on the basis 
of 1H and 13C NMR, COSY, NOE, and HMQC data in 2003. These structures were 
confirmed by analysis of a 13C-labeled sample of archazolid A obtained by the feeding of 
13C-enriched acetate and methionine to Archangium gephyra.3  The absolute and relative 
stereochemistry of archazolid A and B were determined by Menche et al. in 2006 by high 
field NMR studies in combination with molecular modeling and derivatization.1 This was 
followed by synthetic confirmation of archazolid A and B in 2007 by Menche et al. and 
Trauner et al., respectively.4,5 Perhaps inspired by interesting structural features and 
biological properties, the search for novel structural analogues of this interesting family 
of natural products continued. A. gephyra is the source for archazolid A, B and F, while 
another myxobacterial strain, Cystobacter violaceus, produces glycosylated archazolids 




inhibit vacuolar-type ATPases (V-ATPases). Inhibition of this molecular target is 









Figure 1-1. Archazolid family of natural products. 
1.2 Biological Importance of the Archazolids: V-ATPase Inhibition 
V-ATPases are a family of complex multisubunit ATP-dependent proton pumps 
that regulate pH in endomembrane systems (Figure 1-2). V-ATPases are found in 
intracellular organelles (lysosomes, endosomes, and secretory vesicles) and the plasma 
membrane. The V-ATPase plays an important role in the endocytosis pathway9 and 
trafficking of receptor-ligand complexes by acidifying intracellular organelles as well as 
the extracellular space.10 V-ATPases contain two major domains: the cytoplasmic V1 
domain, and the membrane bound Vo domain. The V1 domain is comprised of 8 subunits 
A (R1 = H, R2 = Me, R3 = H, R4 = Me), 2,3
B (R1 = H, R2 =Me, R3 = H, R4 = H), 2,3
C (R1 = H, R2 = Me, R3 = ß-glucoside, R4 = Me), 2,3
D (R1 = H, R2 = CH2OH, R
3 = ß-glucoside, R4 = Me), 2,3
E (R1 = ß-glucoside,R2 = Me, R3 = H, R4 = Me), 2,3



















(A-H) and is responsible for ATP-hydrolysis. The Vo domain is comprised of subunits a, 
d, e, and six c subunits (c, c’, c”). The c subunits, each composed of 4 alpha-helices, form 
a H+- binding rotor responsible for transporting protons from the cytoplasm to the 









Figure 1-2. The V-ATPase. 
 In recent years, it has been observed that an overexpression of the V-ATPase on 
the plasma membrane correlates with an invasive phenotype of cancer cells.12 This 
overexpression creates an acidic extracellular pH, which is known to be a key factor in 
activating proteases involved in tumor cell invasion.13 Taken together, these data show 
that V-ATPase upregulation and overexpression is a well-designed compensatory 




Consequently, inhibitors of the V-ATPase could be promising and novel 
anticancer therapeutics and several inhibitors have been developed in order to study the 
effect of V-ATPase inhibition.14 Two well-studied inhibitors are concanamycin and 
bafilomycin, members of the plecomacrolide antibiotic family of natural products (Figure 










Figure 1-3. Plecomacrolide natural products bafilomycin and concanamycin. 
meaning “1 fold” describes their unique secondary structure formed by the polyketide 
chain that is pendant to the macrolactone core. They are typically found with 16 or 18-
membered macrolactone cores.15 At concentrations in the nanomolar range, bafilomycin 




processes such as endocytosis and exocytosis.16 However, detailed information on the 
signaling pathways affected by V-ATPase inhibition is limited for these molecules and 
others.17 The archazolids have since emerged as superior V-ATPase inhibitors, in that 
they are potent and highly selective toward V-ATPases (Table 1-1). Bafilomycin and 
concanamycin directly impair the function of the mitochondria via interactions with 
phosphorylation ATPases (P- ATPases) at concentrations in the macromolar range, an 
effect not observed when treating isolated rat liver cells with archazolid B. These 
differences can be attributed to the unique molecular mechanism of action of the 
plecomacrolides and the archazolids. The plecomacrolides bind between two c subunits, 
whereas the archazolids bind within a single c subunit (Figure 1-4).18 The archazolids 
have since emerged over other V-ATPase inhibitors as powerful chemical tools in 
deciphering the role of the V-ATPase in tumor environments. 













archazolid A 0.81 
archazolid B 1.1 
archazolid C 1600 
archazolid D 330 
archazolid E 510 












Figure 1-4. Binding sites of the archazolids (blue stars) and the plecomacrolides (red 
stars).  
Three studies by Vollmar and et al. have been published in the last two years that 
highlight the use of the archazolids and seek to define the effects of cancer cell V-
ATPase inhibition at the specific cell signaling level. In 2012, it was found that 
pretreatment of cancer cells with archazolid A effectively decreases metastasis of breast 
tumors by impairing the trafficking and activation of EGFR and Rho-GTPase Rac1, both 
of which are pivotal for the movement of cells.12 In 2013, cell death induction involving 
archazolid B activating the cellular stress response was demonstrated.19 Also in 2013, it 
was shown that V-ATPase inhibition by archazolid20 leads to apoptosis and growth 
inhibition of the trastuzumab-resistant cell line JIMT-1 in vitro as well as in vivo. 




surface accompany this effect. It was demonstrated that archazolid inhibits growth of 
trastuzumab-resistant tumor cells by targeting HER2 via a mechanism different from 
direct binding to the receptor and that the V-ATPase could thus serve as a promising 
target for the treatment of trastuzumab-resistant tumors.21 
Clearly, the V-ATPase serves as an important therapeutic target for cancer 
research, and the archazolids are emerging as powerful chemical tools in order to gain a 
clearer understanding of the role of the V-ATPase in tumor environments. The 
archazolids are thus important synthetic targets to this end, and the following section will 














Chapter 2. Previous Syntheses of the Archazolids 
2.1 Synthesis of Archazolid A 
In 2007, Menche and Hassfeld successfully synthesized archazolid A in 20 steps 
with a 4% overall yield (longest linear sequence). Their synthetic approach relied on 
assembly of three main building blocks of similar complexity, as presented in the 
retrosynthetic plan in Scheme 2-1.22  






The 13E-alkene was envisioned to arise from an aldol condensation between 2 
and 3, while the 18E,20E diene was planned to arise from a Heck coupling of 2 with 4. A 
Horner-Wadsworth-Emmons (HWE) olefination was used to deliver the final 




for ring-closure. This modular total synthesis offers potential for developing large 
quantities of archazolid A as well as structural analogues for SAR studies.23 
The synthesis of the C3-C11 fragment 3 (Scheme 2-2) began with an anti-selective 
boron-mediated Paterson aldol reaction with 5 and aldehyde 6 to set the stereocenters at 
C7 and C8 in 7.
24 TBS protection followed by reduction and periodate cleavage afforded 
aldehyde 8 in 85% over three steps. Aldehyde 8 was subjected to a Still-Gennari 
modified HWE with phosphonate 9 to give 10 containing the 13E-alkene.25 Following 
conversion of 10 to enal 11 using DIBAl-H and allyic oxidation with MnO2, a second 
Still-Gennari HWE was employed to install the 11E-alkene with high stereoselectivity. 
Fragment 3 was completed with a DIBAl-H reduction of the ester followed by oxidation 
of the resulting primary alcohol using Dess-Martin periodinane. 











The synthesis of 2 (Scheme 2-3) began with a LiAlH4 reduction and allylic 
oxidation (MnO2) of vinyl iodide 13
26 to give aldehyde 14. An Abiko-Masamune anti-
aldol reaction was highlighted as a pivotal step to install the stereocenters at C16 and 
C17.
27 After methylation of the secondary alcohol in 16 with silver oxide and methyl 
iodide, the ephedrine auxiliary was removed reductively with LiAlH4 to give 17, which 
was converted to 2 via DMP oxidation, addition of MeMgBr, and DMP oxidation. 
Scheme 2-3. Synthesis of fragment 2. 
 
Preparation of 4 began with α-hydroxyacid 18 being converted into thioamide 19 
in four steps via amide formation, TBS protection, and treatment with Lawesson reagent 
(Scheme 2-4). Thiazole 21 was formed via cyclization of thioamide 19 with 20, the free 
hydroxyl was liberated with TBAF, and the carbamate was installed over two steps. In a 
subsequent publication regarding the modular total synthesis of archazolids A and B, the 
authors note that epimerization of the hydroxyl group occured upon thiazole formation 
(*).28 This was remedied by re-oxidation with DMP and a selective CBS reduction. This 
issue, however, was not reported in the initial synthesis of archazolid A. Following 




aldehyde. A Brown’s asymmetric crotylation gave alcohol 4 with excellent 
diastereoselectively and a moderate yield of 65%.29  
Scheme 2-4. Synthesis of fragment 4. 
 
The strategy for fragment coupling relied on first joining methyl ketone 2 and 
aldehyde 3 and was carried out using a boron-mediated aldol condensation (Scheme 2-5). 
The subsequent Heck reaction of 24 with 4 gave 25 with 6:1 E/Z selectivity after careful 
optimization of reaction conditions. When performed at elevated temperatures (80oC), 
some isomerization at the 11Z-alkene was observed. It was reported that this minor 
stereoisomer could be removed post-macrocylization. Following addition of phosphonate 
26 with use of BOP, PMB removal, and Swern oxidation, 27 was cyclized successfully 
using NaH. CBS reduction of the ketone at C15 gave the desired stereochemistry in high 
diastereoselectivity (ds > 20:1).30 The final step to form 1 was removal of the secondary 




relative and absolute configuration proposals based on spectral data comparison with an 
authentic sample of archazolid A.31 









2.2 Synthesis of Archazolid B 
Inspired by remarkable bioactivity and interesting structural features, Trauner, 
Roethle, and Chen sought to synthesize archazolid B (28) by employing a Hoye relay 
ring-closing metathesis (RRCM), a Stille coupling, and a Kita esterification as shown in 
retrosynthetic scheme 2-6.32 Three main building blocks (29, 30, and 4) lead to a highly 
convergent synthesis with a 19 step longest linear sequence and highlights the use of 
several transition metal-mediated transformations.  
Scheme 2-6. Retrosynthesis of archazolid B by Trauner et al. 
 
The northeastern building block 30 was synthesized beginning with the formation 
of known ynone 33 from the available (S)-Roche ester (32) (Scheme 2-7)33. Alkyne 33 
underwent a highly diastereoselective reduction with (S)-alpine borane to give a 
propargylic alchohol, which was protected with triisopropylsilyl ether and then 
selectively desilylated to give primary alcohol 34. Oxidation to the corresponding 




transformation (a special example of the Wittig involving formation of a 
dibromocarbene) was subsequently used to obtain 35.  A Tanino and Miyashiti method 
for installation of a Z vinyl iodide was employed followed by exchange of the secondary 
silyl protecting group for a tert-butylcarbonate provided 36.34 A highly selective Trost 
Alder-ene reaction with 3-butenol afforded triene 37.35 Oxidation of allylic alcohol 37 to 
the corresponding aldehyde with Dess-Martin periodinane followed by Pinnick oxidation 
gave allylic carboxylic acid 30.  







The synthesis of the southwestern thiazole fragment 4 commenced from the 
known hydroxylalkyl thiazolecarboxylate 38 (available from leucine in 6 steps, the same 















































followed by selective reduction of the ester to an aldehyde and a Brown crotylation gave 
multigram quantities of the fragment (Scheme 2-8).8 
Scheme 2-8. Synthesis of fragment 4.  
  
  
 The synthesis of fragment 29 began with obtaining iodide 39 in three steps 
from propargyl alcohol. Reduction of the ester with DIBAl-H followed by oxidation with 
Dess-Martin periodinane gave the corresponding aldehyde, which underwent an Evans 
syn-aldol addition with the boron enolate of benzyl oxazolidinone 40 to give 41. 
Transformation to the Weinreb amide followed by silyl protection of the secondary 
alcohol and a phosphonate Claisen reaction gave β-keto phosphonate 42. A HWE 
olefination with enal 43 afforded dienone 44, which then underwent a diastereoselective 
NaBH4 reduction followed by esterification and iodine-tin exchange to give fragment 29 
(Scheme 2-9).  








Base-mediated esterification between 30 and 4 resulted in migration of the C2-C3 
double bond, and so required a Ru-catalyzed activation of 30 as the acyl ketene acetal, as 
described by Kita37, to give 45. Subsequent thermal deprotection of the Boc group gave 
iodide 46, which was then subjected to a modified Liebskind  coupling with vinyl 
stannane 29 to give the metathesis precursor 47.38 The RRCM (this reaction is discussed 
in detail in Section 3.3.4) proceeded in a 27% yield followed by deprotection of the 
secondary alcohol gave archazolid B (28) (Scheme 2-10).39 














45: R = Boc
46: R = H
29
Pd(PPh3)4, CuTC












1. Grubb's II, PhCH3 (27%)








2.3 Modular Total Synthesis of Archazolid A and B 
In 2009, Menche and Hassfelf presented a modular total synthesis of archazolid A 
(1) and B (28), developed from the previously reported synthetic strategy.7 Much of the 
synthesis of key fragments presented above (2-4) remained the same, but thorough 
optimization of reaction procedures resulted in revision of key transformations. The 
retrosynthesis remained the same, with the key difference being use of phosphonate 26 or 
48 leading to archazolid A or B, respectively (Scheme 2-11).  
Scheme 2-11. Revised retrosynthesis for modular approach to archazolids A and B. 
 
For the synthesis of building block 4, it was reported that the previous method for 
installing the thiazole ring resulted in epimerization of the free hydroxyl stereocenter. 
This was remedied by oxidation of 21 (mixture of stereoisomers) to the corresponding 
ketone 49 followed by reduction with (R)-CBS to give enantiopure 21 (Scheme 2-12). 





Scheme 2-12. Revised strategy for synthesis of 21.  
 
 
Synthesis of building block 2 was reevaluated due to the lengthy stepwise 
procedure previously reported for removal of the Abiki-Masamune auxiliary. It was 
found that activation of the ester carbonyl by coordination to the free hydroxyl using a 
Lewis acid allowed promotion of nucleophilic attack of Weinreb amide 50 to give 51 
(Scheme 2-13). Best results were obtained with the use of i-PrMgCl as the coordinating 
Lewis acid. With this method, the chiral auxiliary can be recovered, adding to the atom 
economy of the process. Weinreb amide 51 could be transformed to methyl ketone 2 in 
two steps (74%).  
Scheme 2-13. Revised strategy for synthesis of fragment 2. 
 
Unreported in the original synthesis of archazolid A, macrocyclization of 27 to 1 




C16/C17) to undergo elimination and thus presented a challenge in affording the final ring 
structure (Figure 2-1). This was overcome serendipitously by use of molecular sieves that 
were present from the drying of the starting material. It is proposed that the molecular 
sieves are essential in this process possibly due to the slightly acidic nature of the 







Figure 2-1. Positions C7-C8 and C16-C17 were prone to elimination under mild reaction 
conditions 
 
To demonstrate the modularity of their synthetic approach, synthesis of 28 was 
approached using a different order in the fragment coupling processes. This involved an 
intermolecular HWE of phosphonate 52 (afforded by the addition of phosphonate 48 with 
BOP to building block 4) and aldehyde 53 (afforded by deprotecting the primary PMB 
group on 24 followed by Swern oxidation). Following the HWE olefination, an 
intramolecular Heck macrocyclization was performed, following CBS reduction and 




Scheme 2-14. Completion of the synthesis of archazolid B (28). 
 
 
2.4 Highly stereo- and regioselective approach to the C9-C12 fragment of the 
archazolids. 
 In 2007, Negishi and Huang described an elegant approach to the synthetically 
challenging C9-C12 (Z,Z)-1,1,3,4-tetrasubstituted 1,3-diene present in the macrocylic core 
of the archazolids.40 This was accomplished by a 1-halo-1-alkyne hydroboration followed 
by migratory insertion of 55 and a Zn-promoted transmetalative iodinolysis to give 58. A 




conjugated triene 60 in good yields (83% for 60a; 81% for 60b) (Scheme 2-15). Two 
protocols described (Zn-II and Zn-III) have provided potential intermediates for the 
synthesis of the archazolids as isomerically ≥98% pure compounds. To date this group 
has not published any further synthetic work on the archazolids.  





2.5 Synthesis of the Eastern fragment of archazolid A 
 A synthesis of the “Eastern” fragment (C3-C14) of archazolid A as defined by the 
retrosynthesis in Scheme 2-16 was described by our group in 2009.41 The retrosynthetic 
analysis, including a macrocycle formation by ring-closing metathesis (RCM) at C13-C14 




terminal triene 61. This was envisioned to arise from a tandem allylation/elimination 
sequence between 63 and aldehyde 62.  











The synthesis of 61 began with ester 64, prepared as a separable mixture along 
with lactone 65 from 4-hydroxy-2-butanone. TBS protection and DIBAl-H reduction to 
the corresponding primary alcohol 66 was followed by oxidation to the aldehyde (MnO2) 
and and an anti-selective brown crotylation to give 68. To set the stage for the 
allylation/elimination sequence, the free hydroxyl was acylated with methacryloyl 
chloride followed by RCM with 5 mol % Grubbs’ second-generation catalyst (GII) to 











Lactone 69 was partially reduced with DIBAl-H to the corresponding lactol 71, in 
equilibrium with the aldehyde 70. This equilibrium mixture was immediately treated with 
an in situ prepared allylzirconocene 72 and, using basic work-up conditions, the 
intermediate zirconium alkoxide underwent a syn Peterson-type elimination42 to give 
Eastern fragment 61 in 68% yield with a 4:1 Z:E selectivity (Scheme 2-18).  



























Chapter 3: Retrosynthetic Plan and Review of Olefin Metathesis 
3.1 Retrosynthesis 
Structure activity relationship (SAR) studies with natural and synthetic analogues 
have been limited for the archazolid family of natural products. However, as the six 
members of this family have been identified, it has become clear which area of the 
molecule is important for activity. In 2011 Horstmann and Menche published the 
discovery and isolation archazolids E and F, the most recent additions to the pool of 
structurally novel analogues of archazolid A and B.43 In this work, they presented 
findings regarding the activity of the various members in relation to functional group 
differences. Looking at the activities in Table 3-1, it is observed that all glucosylated 
archazolids have a higher L-929 growth inhibition IC50 value (e.g. are less potent) than  














archazolid A 0.81 
archazolid B 1.1 
archazolid C 1600 
archazolid D 330 
archazolid E 510 
archazolid F 0.11 
A (R1 = H, R2 = Me, R3 = H, R4 = Me), 2,3
B (R1 = H, R2 =Me, R3 = H, R4 = H), 2,3
C (R1 = H, R2 = Me, R3 = ß-glucoside, R4 = Me), 2,3
D (R1 = H, R2 = CH2OH, R
3 = ß-glucoside, R4 = Me), 2,3
E (R1 = ß-glucoside,R2 = Me, R3 = H, R4 = Me), 2,3



















the parent archazolids A and B. C15-O-β-glucosylated archazolid E is less potent than A 
or B, but 3 times more potent than the corresponding C7-O-β-glucosylated archazolid E. 
This suggests that the C15-OH may not be as important for binding compared with the C7-
OH, which is in agreement with previous results obtained for a C15-oxo derivative.
44 
Taken together, these data suggest the fragment between C7 and C15 to be part of the 
pharmacophore region of the archazolids that is involved in binding and activity with the 
V-ATPase. In contrast to this, archazolid F, or iso-archazolid B, is 10 times more potent 
than archazolid A or B with an IC50 in the subnanomolar range. These data indicate a 
degree of structural flexibility in the C1 to C4 region is possible while maintaining 
potency.  
SAR studies can be done by simplifying a complex molecule in order to create a 
more expedient synthetic route.45 A logical structural analogue to create is 
dihydroarchazolid B (archDhB) (Figure 3-1). In removing the double bond in the C1 to 
C4 region, it allows us access to a more convergent synthesis by shifting the 
disconnection point to the lactone moiety as opposed to a HWE disconnection between 
C2 and C3, as previously planned for the synthesis of archazolid A.
46 This simplification 
also allows us to avoid instability issues potentially caused by the enone present in 











Figure 3-1. Dihydroarchazolid B. 
Our retrosynthetic plan presented in Scheme 3-1 relies on two key disconnections 
to give fragments of similar complexity. Western fragment W1 and Eastern fragment E1 
are envisioned to be coupled by esterification adjacent to C1 followed by RCM between 
C13 and C14. With our retrosynthetic strategy towards archDhB analogue hinging on 
macrocycle formation via RCM, a discussion of the details and importance of metathesis 
in synthesis is important. The purpose of the following sections is to briefly review 
alkene metathesis beginning with a general overview of catalysts and mechanism, 
followed by a discussion of the various transformations afforded by employing this 
technique. Alkene reactivity categorization for the prediction of metathesis outcomes will 














3.2. Alkene Metathesis 
Much progress in the field of organic chemistry is dependent on the ability to 
construct carbon frameworks through carbon-carbon bond formation. The synthetic 
chemist has a toolbox of reactions to facilitate this, for example: the Grignard47, Wittig48, 
and Diels-Alder49 reactions. More recently, two additional carbon-carbon bond forming 
processes have been developed: palladium-catalyzed cross coupling and olefin metathesis 
reactions (both of which have resulted in two recent Nobel prizes). Metathesis reactions 
have reshaped the landscape of synthetic organic chemistry, arguably more than any 
other single process, over the last 15 years.50 
Alkenes can be rationalized as two alkylidene (=CHR) groups combined via a 
double bond and metathesis is defined as any reaction that exchanges these alkylidene 





































Figure 3-2. General schematic for alkene metathesis.  
 
3.3 Metathesis Catalysts 
The outcome of olefin metathesis is sensitive to several factors. A very important 
consideration in performing these reactions is choice of catalyst. The first metathesis 
process, described in the 1950s, used an aluminum/molybdenum catalyst whose exact 
structure is unknown.51 Metathesis catalysts (Figure 3-3) were undefined “black box” 
entities until 1990, when Schrock and coworkers developed molybdenum catalyst S.52 
The introduction of catalyst S was a groundbreaking advancement in catalyst design 
because it tolerated a wider range of functional groups than earlier undefined catalysts. In 
recent years, it has been found to be useful for the formation of sterically crowded 
systems.53 The prominent drawback of S is its marked sensitivity to oxygen and moisture 
as well as to polar or protic functional groups.54 In 1992, Grubbs and coworkers 
developed the ruthenium-based catalyst GI (Grubbs 1st-generation catalyst). Catalyst GI 
tolerates a wider range of functional groups and is less oxygen and moisture sensitive 












































Further catalyst re-design involving the specific tuning of auxiliary ligands bound 
to the ruthenium led to the Grubbs 2nd Generation catalyst GII. The replacement of one 
of the phosphine ligands with an N-heterocyclic carbene ligand led to an increase in 
catalytic activity, thermal stability, and functional group tolerance.56,57 A valuable 
alternative to GII that provides further stability and better reactivity is the Grubbs-
Hoveyda catalyst GH, where the benzylidene ligand has a chelated ortho-isopropoxy 
group in place of the phosphine ligand.58 The broad utility of alkene metathesis is due 
largely to the superb selectivity and high functional group compatibility of these 













3.4 Alkene Metathesis Mechanism          
  The generally accepted mechanism of alkene metathesis was originally proposed 
and published by Chauvin and Hérrison in 1971.60 Experimental evidence in the Casey61, 
Katz62, and Grubbs63 groups provided validation for this mechanism. It is important to 
note that the term “catalyst” refers to a chemical entity in a reaction that is regenerated 
after each “cycle” of a reaction. In alkene metathesis, the original catalyst is not 
regenerated. Instead, the metal center serves as an “initiator” for each metathesis event. 
This “initiator” species serves as the active catalyst. In the case of the Grubbs catalysts, 
styrene is released upon engangement of one of the alkene substrates. In successive 
cycles, ethylene is generated after each metathesis event. This is evident in the catalytic 
cycle of alkene metathesis (Scheme 3-2). Key intermediates in the catalytic cycle are a 
metal carbene (I, III) and a metallocyclobutane (II, IV). The starting point for the 
catalytic cycle is metal carbene Ru-I after the initial release of styrene and the first 
metathesis event to form a new alkene between R1 and R2. This metal carbene reacts with 
the first alkene partner containing R1 to generate metallocylobutane Ru-II. Upon 
formation of metal carbene Ru-III, ethylene is released and the alkene partner containing 
R2 can interact with Ru-III to form metallocyclobutane Ru-IV. The original metal 
carbene Ru-I is then regenerated and the new alkene is liberated from the cycle. This 
cycle continues until either the reaction is quenched (with an excess of an alkene partner 
resulting in an inactive catalyst, for example) or the lifetime of the catalyst expires.  
 












































3.5 Types of Transformations in Alkene Metathesis 
3.5.1  Cross Metathesis 






Alkene cross metathesis (CM) is a convenient route to functionalized and higher 
olefins from simpler alkene precursors. Di-, tri- and even tetra-substituted alkenes can be 
accessed via this route.64,65 A general scheme is shown (Scheme 3-3) for CM of two 
terminal alkenes to create a heterodimer and two homodimers. The major issues with CM 
are that homodimerization must be controlled to attain useful yields of the heterodimer 
CM product and E/Z ratios are difficult to control and predict. These issues have 
prevented CM from sharing the same spotlight as other metathesis transformations. As a 
wealth of new data has emerged over the last decade, however, models have been 
developed that can predict the outcome of these metathesis events.66 Along with the 
introduction GII, this prediction model (discussed in detail below) has allowed for CM to 
be highlighted in the synthesis of several complex natural products. As an example, 






















Figure 3-4. Dolabelide C. 








Treatment of the gem-disubstituted alkene D1 with boronate B1 in the presence of 
GII (5 mol %) afforded the corresponding vinyl iodide D2 with relative ease (Scheme 3-




C1-C15 fragment could be isolated in 55% yield. The CM between enone D3and gem-
disubstituted alkene D4 to form trisubstituted alkene D5 was more challenging. 
Optimization experiments finally afforded the transformation that resulted in the C16-C30 
fragment in 49% yield as a mixture of 4:1 E/Z isomers. 
3.5.2 Ring-Opening Metathesis 




Ring-opening metathesis (ROM) (Scheme 3-5) of cyclic olefins has been widely 
used for the process of “living” polymerization.68 ROM polymerization (ROMP) occurs 
with the use of a metathesis catalyst releasing ring strain to create two terminal alkenes 
that can then homodimerize with other ring-opened products in order to produce a 
polymeric chain. The attractiveness of ROM in synthesis is the ability to perform a ROM 
in tandem with a second transformation. In the presence of a second alkene partner, the 
opened ring undergoes a CM process (Scheme 3-6). The combination of ring-opening 
and cross metathesis (ROM-CM) is particularly useful for the selective cross coupling 
between strained bycyclic olefins and monosubstituted olefins.69 An interesting example 
of the usefulness of ROM taking advantage of ring strain is presented in the synthesis of 




50oC, 10h) in benzene under an ethylene atmosphere produced cylooctadiene Ast2 in 
74% yield. The intermediate dialkyl cyclobutane formed initially by ROM proceeds with 
a facile Cope rearrangement to afford the desired ring structure present in the final target.  

























3.5.3 Ring-Closing Metathesis 




One of the most powerful methods for ring closure is the ring closing metathesis 
reaction (RCM) (Scheme 3-8). RCM is simply a variation of alkene cross metathesis 
performed intramolecularly. This process has been particularly useful in allowing the 
closure of difficult to form rings, such as 7- and 8-membered rings. RCM has also found 
fame in multistep target-oriented synthesis as a seemingly endless collection of ring 
systems can be created with this method. Common, medium, large, carbocylclic or 
heterocyclic rings can be formed. Macrocylizations using RCM are increasingly common 
in natural product synthesis.71 However, the product distribution of monomer and 
oligomers is often problematic in the formation of medium to large rings. Careful tuning 
of concentration, catalyst type, and temperature has been shown to have a significant 
impact on the outcome of the RCM product:oligomer ratio. This heedful optimization 
was performed successfully in the synthesis of the 16-membered macrolactone epothilone 
490 by Yamamoto et al. (Scheme 3-9).72 During synthesis for SAR studies, it was found 
that increased steric bulk allylic to one of the terminal alkenes drastically decreased yield 




improved greatly. If formation of the monomer is entropically favored over that of the 
dimer, the kinetic ratio of the two products should shift toward the monomer at higher 
temperature. This was indeed the case, and this methodology was applied to two other 
independent and highly functionalized systems in the same study. This work highlights 
the utility of RCM: substrate effects (steric bulk) can often be overcome by tuning 
reaction conditions. A wide variety of macrocycles can thus be accessed via RCM to 
create highly convergent syntheses where olefins are embedded in the ring system. 
Chemists are emboldened to commit their molecules for ring closure events over CM, 
where one may have to choose precious material to be subjected in excess in order to 
favor desired product.  












Although RCM is a generally applicable method for ring closure, this 
applicability is not universal. Boundaries arise when attempting to apply this efficient 
technology to increasingly complex synthetic targets. In particular, RCM can fail when 
the substrate terminal alkenes are sterically hindered or electronically deactivated. The 
concept of a relay ring-closing metathesis (RRCM) was developed by the Hoye group 
nearly a decade ago (Scheme 3-10) and can circumvent these issues.73 The RRCM 
concept allows for directing metal movement throughout the RCM sequence and, in 
effect, allows the cyclization of otherwise unruly substrates. A relay tether can consist of 
an alkyl chain, typically 5 or 6 carbons in length, with a non-hindered terminal alkene 
such that, upon metal initiation with the relay terminal alkene, cyclization occurs quickly 
due the nature of 5- and 6-membered ring formation being a fast process. The relay tether 
serves to pass the metal into an otherwise inaccessible (sterically hindered or 
electronically deactivated) alkene through a sacrificial RCM process. In the example used 
by Hoye in 2004, diene H1 was unreactive to the GI catalyst and intermolecular 
incorporation of the ruthenium center was not possible. However, when modified relay 
substrate H2 was subjected to GI, intermediate H3 was formed, and a smooth cyclization 
resulted to give intermediate H4. The final cyclopentene H5 was formed quickly. RRCM 
serves as a nice compliment to traditional RCM, particularly in synthesis of complex 
macrocycles. Generally, these syntheses employ convergent and modular strategies such 
that installation of a relay tether becomes a relatively simple task, even when a RRCM 
















This technology was highlighted in the synthesis of archazolid B by Trauner and 
coworkers in 2007 (Scheme 3-11).74 In this example, an RRCM strategy was devised in 
order to minimize the partial complication of initial activation at C21, from which they 


















3.6 Categorization of Alkenes for Predictable Reaction Outcomes 
Alkene metathesis is an enormously powerful tool to the organic chemist and it is 
clear that endless synthetic possibilities exist when applying this methodology. As more 
synthetic challenges are overcome with metathesis, the pool of information regarding 
reaction optimization, catalyst selection, and substrate selection grows. In order to 
successfully input lessons from other researchers into individual synthetic goals, it is 
pertinent that there be some organization to the immense amount of information 




metathesis that will briefly be discussed here.20 This model systematically categorizes 
olefins in terms of their reactivity, and this can be used to predict both selective and non-
selective CM reactions with catalysts having varying activities.  
The complex interplay of steric and electronic factors determining the ability of 
sets of olefins to selectively undergo CM necessitated a direct and empirical ordering of 
olefin reactivity. The expedient method used for this ranking was inspection of the ability 
of olefins to homodimerize. Specifically, the ability of olefin homodimerization relative 
to other olefins was studied. This analysis led to a general model comprising four olefin 
types, I-IV (Figure 3-5). Type I olefins are those that can undergo rapid 
homodimerization, and whose homodimers can participate in CM. Type II olefins 
homodimerize slowly and their homodimers are sparingly consumed. Type III olefins do 
not homodimerize but are still able to undergo CM with Type I and Type II olefins. Type 
IV olefins are not able to participate in CM but do not inhibit catalyst activity towards 












 A second component of this model that allows for outcome predictions in 
metathesis events is categorization of catalyst activity. While tuning of electronic or 
steric properties on an olefin (by use of different protecting groups, for example) can be 
sufficient to change reactivity, simply choosing a catalyst with different activity can elicit 
the same effect. GII is able to use stilbene, for example, as an efficient CM partner, 
whereas S and GI are not reactive towards this substrate.20     
 This model can be applied CM with different combinations of olefins and allows 
for reaction predictability. In the CM of two Type I olefins, the rates of 
homodimerization are similar to the reaction rates of the homodimers. In reactions of this 
type, the desired product is equilibrated with the homodimers through secondary 
metathesis reactions and this gives a statistical product mixture. In order to provide 90% 
of the CM product, one olefin must be in 10 equiv. excess relative to the other partner. To 
avoid these statistical mixtures, CM reactions can be designed using olefins of two 
different types. This is effective in selective CM because the rates of dimerization are 
significantly different/slower than the rate of product formation. In the combination of 
Type I olefins with Type II or Type III, the Type I olefin homodimerizes and then 
undergoes secondary metathesis with the Type II/III olefin. In the case of Type II and 
Type III olefins, where both dimerize at slower rates than product formation, selective 
CM can be carried out.  





3.7 Retrosynthetic approach based on alkene reactivity 
 Alkene reactivity categorization was considered in our retrosynthetic plan for 
RCM between C13 and C14 due to the higher reactivity of monosubstituted (terminal) 
alkenes versus di-, tri-, and tetrasubstituted alkenes as noted in Chaterjee’s model. The 
general pattern that more substitution on a substrate decreases reactivity demonstrates 
that steric bulk prevents the incorporation of a metal carbenoid in the substrate. Our 
archazolid target contains only 2 disubstituted alkenes, and 4 trisubstituted alkenes 
(Figure 3-6). It was demonstrated in Trauner’s synthesis of archazolid B that an RCM to 
complete the macrocycle between C20 and C21 required the use of a relay (RRCM) to 
prevent unwanted methathesis events and resulted in a low yield (27%, Scheme 3-11). 
This example further bolstered our decision to make a retrosynthetic disconnection 
between C13 and C14, along with the fact that our retrosynthetic disconnections result in 
two fragments of manageable size. It has also been demonstrated that allylic methyl 
groups can deactivate a substrate towards metathesis (C22) 
75, while allylic hydroxyl 










Chapter 4. Work Towards the Total Synthesis of Dihydroarchazolid B 
 The work presented here is focused on the synthesis of the Western fragment of 
archDhB towards a completion of the synthesis via esterification with the Eastern 
fragment E1 and macrocyclization. This chapter begins with the synthesis of the Western 
fragment as previously reported by the O’Neil group in 2011.77 While many of the 
reactions have previously been described, much of the work here has been focused on 
scaling up and optimizing these reactions. This discussion of reactions is followed by 
results from initial macrocylization attempts, a redesign of the western fragment synthesis 
featuring a different protecting group strategy following these attempts, and subsequent 
RCM of this new substrate. 
4.1 Synthesis of the Western Fragment 
 The Western fragment (W1) can be further broken down into two fragments, so-
called Southwest (SW) and the Northwest (NW) fragments, by an organometallic 
addition. The fragment NW was envisioned to arise from a HWE olefination between 

















The synthesis of W4 begian with a TBS protection of the readily available (R)-
Roche ester followed by cold DIBAl-H reduction to the corresponding aldehyde W5. 
Aldehyde W5 underwent a Wittig olefination with the phosphorane W6 to deliver the E-
alkene geometry with an E:Z ratio greater than 10:1 in W7 (Scheme 4-2). This selectivity 
is due to the stability of the ylide as a result of electron withdrawing groups adjacent to 
the negatively charged carbanion formed from deprotonation. Reaction of a stabilized 
ylide is under thermodynamic control, and thus the thermodynamic trans-oxophosphetane 
and resulting E-alkene is obtained as the major product (for comparison, unstabilized 
ylides lead to the kinetic product, ie the Z-alkene, Scheme 4-3).78 W7 was converted to 
the corresponding primary alcohol with a DIBAL-H reduction followed by Swern 
















 The synthesis of phosphonate W3 began by acylating oxizoldinone W8 with 
propionyl chloride to give W9 in preparation for a titanium-mediated syn-Evan’s aldol 
reaction with acrolein (Scheme 4-4).79 The diastereoselectivity of the two newly formed 
stereocenters is determined by the transition state shown in Figure 4-1, where a Z-enolate  




























Figure 4-1. Syn-aldol selectivity transition state. 
is exclusively formed, dipole minimization sets the position of the auxiliary group 
leading to the facial selectivity of aldehyde approach, and the R-group occupies a 
preferred equatorial position. Combined, this leads to the syn configuration of the methyl 
group and secondary alcohol in W10. Following the aldol reaction, the auxiliary group 
was cleaved by substitution with N,O-dimethylhydroxyl amine and TBS protected to give 
the Weinreb amide W11.80 From here, W11 was converted into the corresponding 
ketophosphonate W3 via amide displacement with diethyl ethyl phosphonate (Scheme 4-
5). 
Scheme 4-5. Synthesis of phosphonate W3. 
 
 
To complete the NW fragment, a HWE81 olefination as described by Paterson was 
carried out between phosphonate W3 and aldehyde W482 with Ba(OH)2.




selectivity of this process is said to be enhanced by the microcrystalline structure of the 
barium hydroxide as well as the bulkiness of the phosphonate. Following the formation of 
W12 from the HWE, a previously described selective NaBH4 reduction
84 to give alcohol 
W13 was followed by methylation with methyl triflate to afford methyl ether NW 
(Scheme 4-6).  
Scheme 4-6. Synthesis of the NW fragment. 
 
 Fragment SW was synthesized beginning with selective lithium-halogen 
exchange of 2,4-dibromothiazole and subsequent organometallic addition  into ethyl 
isovalerate derived Weinreb amide W14.85 The resulting ketone W15 was selectively 
reduced to the corresponding alcohol with (R)-(+)-CBS (ee >95%)86 followed by TES 





Scheme 4-7.  Synthesis of the SW fragment. 
 
 Selective primary TBS removal87 followed by mild Dess-Martin periodinane88 
oxidation of fragment NW gave aldehyde W16, setting the stage for coupling with a 
fragment SW-derived organometallic reagent (Scheme 4-8).  
Scheme 4-8. Selective deprotection of a primary TBS group. 
 
Aldehyde W16 and fragment SW were coupled via organometallic addition after 
lithium halogen exchange on the bromothiazole. The resulting alcohol W17 was found to 
be a 2.5:1 (W17a:W17b) mixture of products in excess of the undesired diastereomer as 
a result of Felkin-control.89 Oxidation with Dess-Martin periodinane to the corresponding 
ketone followed by selective reduction to the desired diastereomer with L-Selectride 




best balance of yield to selectivity, with a 73% yield and a greater than 10:1 mixture of 
diastereomers (Scheme 4-9). 
Scheme 4-9. Thiazole coupling and L-Selectride reduction. 
 
Following acylation of alcohol W17b, the secondary TES protecting group was 
removed in the presence of the secondary TBS group to give alcohol W19. The 
carbamate was then added with methyl amine and carbonyldiimidazole and DIBAl-H was 












4.2 Fragment Coupling and RCM Results. 
W1 was coupled with W2 via a Yamaguchi style esterification91 to give WE with a yield 
of 70% (Scheme 4-11).  
Scheme 4-11. Yamaguchi esterification. 
 
With the TBS protected WE in hand, RCM was attempted with a variety of 
conditions (Table 4-1). In all cases, we were not graced with the presence of the RCM 
product and observed either starting material or decomposition. Higher temperatures 




reactions performed at room temperature or 50oC. We attributed this result to the bulky 
TBS group flanking the C14 terminal olefin preventing catalyst engagement at that 
position (Scheme 4-12). To remedy this, we envisioned removing the TBS group at C15, 
but all conditions tried for deprotection proved unsuccessful (Scheme 4-13).  
Table 4-1. RCM conditions and results. 
Catalyst Solvent Temp  Time result 
GII DCM rt 24 h SM 
GII DCM 45 ºC 24 h mostly SMb) 
GII PhMe 50 ºC 24 h mostly SMb) 
GI DCM rt 24 h SM 
GI PhMe 50 ºC 24 h mostly SMb) 
GI PhMe 80 ºC 24 h complex mix 
GI PhMe 110 ºC 24 h complex mix 
GH DCM rt 24 h SM 
GH PhMe 50 ºC 24 h mostly SMb) 
GH PhMe 80 ºC 24 h complex mix 
GH PhMe 110 ºC 24 h complex mix 
     
a)Reactions from room temperature (rt) to 50 ºC were performed using 10 mol% catalyst (added in two 5% 
batches, with the second at roughly half of the time indicated). Those performed at 80 and 110 ºC used a single 
lot of 5% catalyst added once the reaction mixture had reached the desired temperature. All reactions were 
performed in degassed solvent (0.005 M) under a steady stream of N2. 
b)No RCM product was detected by MS. 
 








Scheme 4-13. Failure to remove the secondary TBS group. 
 
A protection group swap was then envisioned in order to introduce a more labile TES 
group that could be removed without decomposition of the somewhat sensitive terminal 
triene.  





Figure 4-2. Second generation Western fragment (W2).  
Due to our need to selectively remove both a primary TBS group at C23 as well as 




installed early in the synthesis of the second-generation Western fragment W2 (Figure 4-
2).  
The synthesis of W2 diverges from the synthesis of W1 following the Dess-
Martin oxidation to give ketone W18. To accomplish this, the ketone was not reduced 
and protected at this stage (as is done for the synthesis of W1) but instead was left in its 
oxidized form until the final step to form W2. As shown in Scheme 4-14, a TES 
deprotection of the secondary alcohol on the thiazole moiety of W18 followed by 
carbamate addition afforded W20. The protection group swap was carried out by 
removing the secondary TBS group with HF/pyridine at C15 and subsequently adding a 
TES group with TES triflate to give TES compound W21. Completion of the synthesis of 
W2 was done with a high-yielding L-Selectride reduction. This gave fragment W2 in 16-
steps and 8.5% yield (longest linear sequence) from W18 as opposed to 16-steps and 
4.7% from our previous synthesis (Ref. Schemes 4-9 and 4-10).  












1. HF-pyr 4o C, 82%


























With W2 in hand, esterification with E1 gave desired product WE2 in 60% yield 
(Scheme 4-15).  





Deprotection at C15 was then achieved with HF/pyr at 4 
oC for 20h. This gave the 
free-hydroxyl WE3 with which the RCM was investigated.  










Table 4-2. RCM conditions and results with free C15-OH. 
Reaction Solvent Temp  Time Result 
1 PhMe 50 ºC 17 h complex mixc 
2 PhMe 80 ºC 17 h complex mixc 
3 PhMea 50 ºC 17 h complex mixc 
4 DCMa 45 ºC 17 h complex mix
c 
5 DCMa,b rt 48 h complex mixc 
 
Reactions were performed using 10-30 mol% catalyst GII added as a single lot with 30-90 mol% p-
benzoquinone (unless otherwise indicated). All reactions were performed in degassed solvent (0.0005 M). 
a)
 Ran under a steady stream of N2. 
b) No p-benzoquinone added. c) No RCM product detected by NMR. Reactions 
1 and 5 showed small amounts of starting material. Reactions 2-4 showed no starting material. In all reactions, 
new peaks may be attributed to oligomer formation and unproductive metathesis with styrene/etc.  
 
 As shown in Scheme 4-16 and Table 4-2, none of the conditions employed for the 
RCM of WE3 afforded the desired product. After reaction 5 showed no difference in the 
1H NMR peak distribution in comparison to reactions 1-4 (see Supporting Information), 
isolation of the likely major product was carried out by preparative TLC on silica. The 
most striking feature observed in the 1H NMR spectrum of the clean major spot obtained 
was the absence of methoxy protons Ha and Hb that have very distinct chemical shifts in 
the starting material spectrum and are not expected to change dramatically upon 









 In order for protons Ha and Hb, and thus the Northwest portion of the molecule, to 
be absent from the major RCM product, it was hypothesized that after the catalyst GII 
engages the terminal double bond adjacent to the free hydroxyl, it might “bite down” 
onto one of the two alkenes between C18 to C21 (Scheme 4-17). It was envisioned that the 
terminal alkene at C14 forms a metallocylcobutane intermediate with either the  





trisubstituted  C18-C19 alkene (red arrow) or disubstituted C20-C21 (blue arrow) and goes 
on to form cyclopentene ring R1 or cycloheptene ring R2, respectively. The remainder of 
the molecule (after ring excision) would then participate in further metathesis events, 
leading to the complex mixtures observed in the 1H NMR spectra for the full-system 
RCM reactions 1-5 (Table 4-2). 
To test this ring excision hypothesis and to confirm formation of R1 or R2, 
compound W21 was subjected to the same dilute RCM conditions used for reaction 1 and 





Scheme 4-18. Formation of R1 from W21 under RCM conditions. 
 
After GC-MS analysis of the crude mixtures resulting from both reactions, parent 
ion peaks for R1 and trace R3, but not for R2, were found. Although 5-membered ring 
formation is energetically favorable over 7-membered ring formation, this result was 
surprising because the RCM reaction occurred on a trisubstituted alkene. There are only a 
few reports of RCM reactions involving trisubstituted double bonds, even when forming 
5- and 6-membered rings, and 92 (as discussed in Chapter 3) a disubstituted alkene should 
be more reactive and more likely to participate in metathesis than a trisubstituted alkene. 
Clearly, the lower in energy 5-membered ring formation trumps this difference in alkene 
reactivity. To confirm that the cyclopentene ring excision was occurring in the RCM 
attempts, R1 was purposefully synthesized as outlined in Scheme 4-19. This began with a 
HWE olefination between the previously synthesized phosphonate W3 and acetyl 
aldehyde followed by selective reduction (NaBH4), methylation and TBS deprotection to 
give W22. Cyclization occurred efficiently to give R1 with no observable starting 




Scheme 4-19. Independently synthesized cyclopentene ring R1.  
 
With R1 successfully synthesized, the presence of the cyclopentene ring R1 in 
crude 1H NMR spectra of the RCM reactions (for WE3 and W21) was confirmed by 
spectral comparison (Figure 4-4). COSY NMR analysis of R1 allowed identification of 
peaks representative of protons Ha-Hc in the clean R1 1H NMR, which are clearly 



















Figure 4-4. 1H NMR (CDCl3, 500 MHz) spectral comparison of clean R1and crude RCM 
reaction 5 (Table 4-2). 
In contrast to the propensity of W21 to undergo a ring excision under RCM 
conditions, the TBS protected compound W20 does not display this effect (Scheme 4-
20). This indicates one of two events occurring: either the TBS is too bulky for the 
catalyst to engage the C14 terminal alkene, or the catalyst engages with the alkene at this 
position, but the TBS group hinders 5-membered ring formation. One way to confirm 
which situation is determining the reactivity of the C14 terminal olefin is to install a relay 
tether for directed metal movement to the alkene in question.  
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Independently synthesized R1 




Scheme 4-20. Unreactivity towards metathesis due to the bulky TBS group. 
 
 In the next chapter, design and application of a relay model for probing the 
reactivity of the C14 terminal olefin will be discussed as a means to overcome the ring-













Chapter 5. Synthetic Studies Towards a RRCM Approach to Dihydroarchazolid B 
 In order to validate a RRCM approach (Section 3.5.4) to archDhB, a model 
compound was designed to initially test the relay concept at an olefin bearing an allylic 
TBS group. A straight chain relay tether six carbons in length was desired for efficient 
triggering and release of cyclopentene, leading to directed metal movement for 
installation of the catalyst at the desired alkene (Scheme 5-1). 




The synthesis of M1 was then envisioned and arose from a cross metathesis 
between compound M2 and M3 and use of our group’s acyloxysulfone “masked alkene” 
chemistry to easily convert a relay tether precursor into the corresponding terminal alkene 
with a sodium mercury amalgam-mediated elimination (Scheme 5-2).93  


















5.1 Synthesis and Evaluation of M1 
Compound M2 was easily accessed from hexanal via addition of vinyl 
magnesium bromide and TBS protection (Scheme 5-3).  




Synthesis of M3  commenced by oxidizing readily available hex-5-en-1-ol to the 
corresponding aldehyde with the Swern method followed by nucleophilic addition of 
methyl phenyl sulfone and trapping of the resulting anion with acetyl chloride in situ 
(Scheme 5-4).  
Scheme 5-4. Synthesis of M3.  
 
 CM between M2 and an excess of M3 was attempted at this stage. However, even 
with moderate catalyst loading (20 mol% GII), only trace amounts of the desired cross 
product were obtained. The major product from this reaction was the dimer M4 of the β-




Scheme 5-5. Unproductive metathesis. 
 
To test the reactivity of the dimer M4, a CM reaction was performed with M2 and 
CM M5 product was obtained in good yield with no observable starting material (Scheme 
5-6). In the initial CM attempt with the monomer M3, the catalyst was likely tied up in 
formation of the dimer, which was shown to be a slow process (starting material M3 
observable after 20 h). By subjecting the dimer M4 in excess in a CM with M2, this 
unproductive metathesis event was avoided and product could be afforded in an efficient 
manner.  





 With M5 in hand, a facile sodium mercury amalgam mediated elimination 
afforded desired relay product M1. Mild RCM conditions allowed the relay to trigger and 
gave back substrate M2 with no starting M5 observable (Scheme 5-7).  
Scheme 5-7. Allylic TBS relay model proof-of-concept study.  
 
5.2 Synthesis of a Functionalized Relay Model 
Encouraged by the success of the M1 relay model study, a more accurate model 
was desired. Initially, CM was attempted between M4 and fully functionalized W1 
(Scheme 5-8).  





With multiple attempts resulting in complex mixtures and only small amounts of 
desired CM product, this approach was deemed inefficient. To conserve precious W1, a 
simplified model M6 was designed (Figure 5-1) that contains the same stereotriad as W1.  
 
Figure 5-1. Model compound M6. 
Prior to synthetic efforts towards M6, model consistency was tested by 
synthesizing M7 and M8 (Scheme 5-9) for subjection under the same RCM conditions as 
for W20 and W21, respectively. M7 and M8 were easily synthesized with a Paterson-
type HWE olefination between previously made phosphonate W3 and cynammic 
aldehyde followed by selective NaBH4 reduction and methylation with methyl triflate. 
Synthesis of M8 diverged from M7 with a TBS deprotection.  





Subjecting M7 and M8 to RCM conditions used to explore the ring excision 
process with W20 and W21 gave us the expected results. Under RCM conditions, M7 did 
not undergo any reaction, whereas M8 was transformed into the cyclopentene ring R2 
and further metathesis products (Scheme 5-10).  






The model was validated by these results and synthesis of M6 commenced. Initial 
attempts at installing the β-acyloxysulfone tether involved a CM between previously 
reported Weinreb amide W11 and the dimer M4 as well as CM between phosphonate W3 
and monomer M3 (Scheme 5-11).  






























As shown in Scheme 5-11, neither route was feasible as the reaction with W11 
and M4 produced no desired product and the CM product of W3 and M3 proved to be 
very polar and difficult to isolate. Taking these difficulties with the β-acyloxysulfone 
relay tether installation into account, focus was directed towards a different ether 
containing relay tether shown to be effective in RRCM of complex natural products.94 
Scheme 5-12 shows compound M9 arising from a HWE olefination between 
phosphonate M10 and cinnamic aldehyde.  
Scheme 5-12. Retrosynthesis of an ether containing relay model. 
 
The synthesis of M10 proceeded smoothly with ozonolysis of phosphonate W3 
followed by Wittig olefination. Subsequent HWE olefination with cinnamic aldehyde 
gave ketone M11. The ketone was reduced with NaBH4 to give alcohol M12 and 
methylation was then attempted, however the methyl ether was not obtained under any of 




Scheme 5-13. Efforts towards synthesizing an ether containing relay compound. 
 
 
This route was abandoned and an alternative synthesis of M6 was then designed 
based on an Evan’s syn-selective aldol reaction between thiazolidine thione M14 and the 
cross product (M13) of relay tether M3 with crotonaldehyde. From here, the auxiliary 
was cleaved with methanol to give methyl ester M15 followed by sodium mercury 
amalgam mediated elimination of the β-acyloxysulfone and TBS protection to give 
compound M16. Conversion of M16 into the phosphonate M17 and subsequent HWE 







Scheme 5-14. Completion of the synthesis of M6. 
 
 
5.3 Evaluation of Functionalized Relay Model M6 
With compound M6 finally in hand, reactions were carried out to assess the 
reactivity of the relay tether and to deduce whether or not the allylic TBS group prevents 
ring excision or simply prevents the catalyst GII from reacting with the terminal alkene 

















Table 5-1. Results of relay studies. 
Reaction Solvent Temp  Time Resulta 
1 PhMe rt 17 h Primarily M6 (trace M18) 
2 PhMe 50 ºC 17 h Mix of all 4 products 
3 PhMe 80 ºC 17 h Mix of W7, R3 (trace M18) 
4 PhMe 110 ºC 17 h Primarily R3 (trace W7) 
5 DCM 45 ºC 17 h Mix of all 4 products 
Reactions performed using 5 mol% catalyst in degassed solvent (0.001 M). b)No RCM product was detected by 

































Unlike the results for the M1 model study, the relay does not trigger at room 
temperature. Elevated temperatures (80 and 110 oC) are needed for relay triggering, a 
surprising result due to the fast nature of cyclopentene formation after catalyst activation. 
Overall, it was found that the TBS group does not hinder 5-membered ring formation. 
The likely scenario for the inability of the terminal alkene with the allylic TBS to 
undergo metathesis reactions is that the catalyst is prevented from accessing the alkene. 
Once the alkene is accessed by the catalyst upon relay triggering, the 5-membered ring 
formation occurs, albeit only at elevated temperatures. A key result of this study was the 
presence of W7 in the reaction mixtures for reactions 2-5 in Table 5-1. These data 
suggest that there is a lifetime of the intermediate M6-1: due to the high dilution, M6-1 
has to go “find” a terminal alkene, such as M6, in order for the formation of W7 to occur 
and it must do this before the formation of R3 (Scheme 5-16). This is a promising result 
and indicates a potential for successful ring closure using a RRCM approach for the full 
system to form archDhB using the 80 °C reaction conditions due to the favorable W7:R3 









Scheme 5-16. Lifetime of intermediate M6-1. 
 












Chapter 6. Conclusion 
6.1 Serendipity Leads to Discovery of a Metathesis Deactivating Stereotriad 
From the work presented in the model studies with M6, a surprising finding was 
the unreactivity of our relay compound. Typically, 5- and 6-membered ring formation 
from a relay tether is fast and occurs with little energetic input (i.e. heat). Comparing the 
behavior of our simplified allylic TBS compound with M6 at room temperature, we were 
able to demonstrate that it is not just the allylic TBS group driving the reactivity of the 
nearby alkene as previously hypothesized for the observed unreactivity of WE1 towards 










Figure 6-1. Comparison of the simplified allylic TBS substrate M4-1 to model 
compound M6 with the stereotriad present in the Western fragment.  
 
Due to the interesting nature of this unexpected differential reactivity and coupled 




position are present in the literature, we were encouraged to explore our results further in 
order to probe the role of contiguous remote functionality in alkene reactivity.  
In order to examine the role of remote functionality, a series of compounds were 
synthesized that differed from the stereotriad in the Western fragment and M6 by either 
lacking a particular stereochemical configuration or by having groups absent from the 
stereotriad altogether. As demonstrated in Scheme 6-1, eliminating the methoxy group as 
a stereocenter in M12 by retaining the planar methyl ester allows relay loss to occur at 
room temperature to give M16. Methyl ester M12 was reduced to the corresponding 
alcohol with DIBAl-H and methylated using methyl triflate and LiHMDS to produce 
M15. With the methoxy group as a free-rotating bond, relay loss occurred under the same 
metathesis conditions as M12 at room temperature to give M17 and orientationally 
divergent CM product M18 in a 1:1 mixture. 
 












These results clearly indicate that it is not just the allylic OTBS even when 
combined with a homoallylic methyl group that is responsible for the relay inactivity seen 
in compound M6.95 When the β-group is the free alcohol M19 (R = H), it remains 
similarly inert to metathesis, demonstrating that additional functionality on the oxygen 
need not be necessary to prevent relay loss (Scheme 6-2).  






Compound M21 was also produced in order to investigate if the α-methyl group 
was playing a key role in this relay loss inhibition (Scheme 6-3).96 This was 
accomplished by metathesis with the acyloxysulfone dimer M4 and M20, followed by 
sodium mercury amalgam mediated elimination of cross product to produce M21. By 
subjecting M21 to the same room temperature metathesis conditions, clean relay loss 









was observed by NMR analysis to give back M20.  
The results in Schemes 6-2 and 6-3 suggest a collective metathesis deactivating 
ability for the three sequential stereocenters flanking the relay tether in compound M6. 
As discussed in Chapter 3, Chaterjee and Grubbs came up with a generalized model to 
categorize alkene reactivity towards metathesis, focusing on the rates of 
homodimerization and secondary metathesis of individual substrates as a guide.64 These 
categorization rules generally focus on olefin substitution patterns and functional groups 
at the allylic position.  
Looking at the results from our series of relay-containing compounds, our data suggests 
the focus on the allylic position to be an oversimplification. In order to accurately 
categorize olefin reactivity, it may be necessary to look at the collective metathesis 
deactivating effects of contiguous functionality. 
 
6.2 Future Work 
In conclusion, we were able to explore the use of a relay tether to potentially 
overcome difficulties associated the ring-closing step towards archDhB. Through this 
exploration, we found conditions that may allow us to perform a RRCM to achieve ring 
closure and subsequently complete the synthesis of this novel archazolid analogue 
(Scheme 6-4). Coming out of this relay work, we also happened upon a synergistic 














              The three stereocenters together are responsible for collectively inhibiting what 
is typically a rapid 5-membered ring forming RCM (Figure 6-2).97 These results are 
pushing our group to further categorize olefins by their metathesis reactivity by 
investigating additional extended functionality systems. Ultimately, these efforts will 
give us a better understanding of the alkene functionality present in the archazolid 
family and allow us to proceed informed in our endeavors towards a completion of a 











7. Experimental  
All reactions were carried out under N2 in flame-dried glassware. The solvents used were 
dried by passing the solvent through a column of activated alumina under nitrogen 
immediately prior to use. All other reagents were purchased and used as received. All 
TLC analysis used 0.25 mm silica layer fluorescence UV254 plates. Flash 
chromatography: SilaCycle silica gel P60 (230-400 mesh). IR: Nicolet iS10 spectrometer, 
wavenumbers (ṽ) in cm-1. NMR: Spectra were recorded on a Varian Mercury 300, or 
Inova 500 spectrometer in the solvents indicated; chemical shifts (δ) are given in ppm, 
coupling constants (J) in Hz. The solvent signals were used as references (CDCl3: δC = 
77.0 ppm; residual CHCl3 in CDCl3: δH = 7.26 ppm). MS(ESI): Waters LCT Premier 



















To a solution of ketone W18 (300 mg, 0.445 mmol) in THF (5 ml) at 0 oC, HF-pyr (70%, 185 µl) 
was added. The resulting solution was kept at 4oC for 20h. The reaction was quenched with aq. 
NaHCO3 (10 ml) and extracted with MTBE (2 x 10 ml). The combined organic extracts were 
dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded the intermediate secondary 
alcohol W17b (211 mg, 82%) as an oil.  
 
IR (ATR) 3405, 2955, 2928, 2855, 2323, 1687, 1472, 1384, 1321, 1250, 1147, 1084, 1024, 920, 
834, 775, 671. 1H NMR (500 MHz, CDCl3): δ 8.12 (s, 1H), 6.45 (ddd, J = 2.3, 10.7, 17.2 Hz, 
1H), 5.83 (m, 3H), 5.16 (dt, J = 1.5, 17.1 Hz, 1H), 5.08 (m, 1H), 5.03 (dt, J = 5, 10.7 Hz, 1H), 
4.61 (d, J = 5.4 Hz, 1H), 4.43 (m, 1H), 3.34 (d, J = 9.9 Hz, 1H), 3.09 (d, J = 1.4 Hz, 3H), 2.68 
(bs, HOH, 1H), 1.91 (m, 1H), 1.79 (t, J = 6.4 Hz, 2H), 1.58 (m, 1H), 1.35 (dd, J = 2.8, 6.9 Hz, 
3H), 1.25 (s, 3H), 1.01 (m, 6H), 0.91 (s, 9H), 0.59 (d, J = 6.9 Hz, 3H), 0.035 (s, 3H), -0.005 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ 195.95, 175.69, 153.99, 141.72, 135.77, 132.67, 129.64, 




24.80, 23.44, 22.07, 18.45, 16.96, 8.85, -3.73, -5.04. HRMS (TOF ES+): Calcd for 
C29H49NO4SSiNa





To a solution of W17b (211 mg, 0.364 mmol) in DCM (7.3 ml), carbonyldiimidazole (240 mg, 
1.46 mmol) was added portion-wise over 1h. The solution was then cooled to 0oC and methyl 
amine was added (2.0 M, 1.1 ml). The resulting mixture was allowed to warm to r.t. over 4 h. The 
reaction was quenched with aq. NaHCO3 (15 ml) and extracted with DCM (2 x 10 ml). The 
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded 
ketone W20 (212 mg, 91%) as an oil.  
 
IR (ATR) 3350, 2956, 2929, 1721, 1687, 1527, 1472, 1386, 1249, 1126, 1085, 919, 833, 774, 
647. 1H NMR (500 MHz, CDCl3): δ 8.11 (d, J = 2.4 Hz, 1H), 6.46 (m, 1H), 6.08 (m, 1H), 5.85 




1H), 4.47 (m, 1H), 3.34 (d, J = 9.9 Hz, 1H), 3.11 (m, 3H), 2.83 (d, J = 4.7 Hz, 3H), 1.89 (m, 2H), 
1.76 (m, 1H), 1.59 (m, 4H), 1.35 (m, 3H), 0.99 (m, 6H), 0.91 (s, 9H), 0.58 (m, 3H), 0.036 (s, 3H), 
-0.007 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 195.90, 171.48, 156.06, 154.24, 141.72, 135.71, 
132.65, 129.76, 127.72, 126.22, 113.99, 88.35, 72.45, 71.37, 55.88, 46.44, 44.28, 41.91, 27.91, 
26.19, 24.80, 23.15, 22.36, 18.46, 16.62, 10.86, 8.87, -3.72, -5.04. HRMS (TOF ES+): Calcd for 
C31H52N2O5SSiNa





To a solution of ketone W20 (42 mg, 0.066 mmol) in THF (1.5 ml) at 0 oC, HF-pyr (70%, 390 µl) 
was added. The resulting solution was kept at r.t. for 20h. The reaction was quenched with aq. 
NaHCO3 (5 ml) and extracted with MTBE (2 x 10 ml). The combined organic extracts were dried 
over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography 
on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded the intermediate secondary alcohol W20-1 





IR (ATR) 3350, 2959, 2929, 2871, 1715, 1687, 1532, 1472, 1368, 1252, 1125, 1082, 964, 920, 
813, 750. 1H NMR (500 MHz, CDCl3): δ 8.11 (s, 1H), 6.44 (ddd, J = 6.1, 10.7, 17.2 Hz, 1H), 
6.08 (dq, J = 2.7, 8.3 Hz, 1H), 5.94-5.79 (m, 3H), 5.29 (dq, J = 1.7, 17.2 Hz, 1H), 5.19 (d, J-10.6 
Hz, 1H), 4.79 (m, HN-H), 4.47 (m , 1H), 4.19 (s, 1H), 3.41 (d, J = 9.7 Hz, 1H), 3.13 (d, J = 8.7 Hz, 
3H), 2.10-2.01 (m, 2H), 1.96-1.83 (m, 4H), 1.77 (m, 1H), 1.65 (s, 3H), 1.35 (dd, J = 1.8, 6.9 Hz, 
3H), 0.98 (m, 6H), 0.67 (dd, J = 7.2, 12.2 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 195.86, 
171.59, 156.11, 154.38, 138.42, 134.36, 133.61, 129.61, 127.58, 126.28, 115.39, 90.82, 75.72, 
56.01, 46.50, 44.38, 40.07, 29.93, 27.92, 24.84, 23.19, 22.36, 16.76, 13.12, 11.28. HRMS (TOF 
ES+): Calcd for C25H38N2O5SNa





To a solution of alcohol W20-1 (27 mg, 0.057 mmol) in DCM (1.0 ml) at -78oC was added 2,6-
lutidine (10 µl, 0.0855 mmol) followed by addition of TES-OTf (15 µl, 0.068 mmol). The 
resulting mixture was stirred at -78oC for 2.5h. The reaction was quenched with aq. NaHCO3 (5 




DCM (2 x 2 ml). The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by flash column chromatography(4:1 to 1:1 hexanes:ethyl 
acetate) afforded the ketone W20-2 (27 mg, 81%) as an oil. 
  
IR (ATR) 3350, 3955, 2929, 2872, 1716, 1688, 1525, 1471, 1418, 1369, 1244, 1126, 1084, 1008, 
963, 919, 828, 730. 1H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 6.46 (m, 1H), 6.28 (t, J = 5.6 
Hz, 1), 5.94-5.76 (m, 3H), 5.17 (d, J = 17.2 Hz, 1H), 5.03 (dd, J = 1.2, 10.4 Hz, 1H), 4.78 (d, J = 
4.1 Hz, 1H), 4.64 (d, J = 5.7 Hz, 1H), 4.46 (q, J = 6.9 Hz, 1H), 3.35 (d, J = 10 Hz, 1H), 3.12 (d, J 
= 5.4 Hz, 3H), 2.83 (d, J = 4.8 Hz, 3H), 1.89 (m, 2H), 1.77 (m, 1H), 1.60 (m, 1H), 1.59 (s, 3H), 
1.35 (dd, J = 2.2., 6.8 Hz, 3H), 0.96 (m, 15H), 0.58 (m, 9H). 13C NMR (75 MHz, CDCl3): δ 
195.90, 171.48, 171.16, 156.07, 154.27, 141.87, 135.73, 132.83, 129.77, 127.74, 126.20, 113.81, 
88.39, 72.46, 71.78, 55.85, 46.46, 44.30, 41.97, 27.90, 24.82, 23.15, 22.37, 16.63, 10.88, 8.91, 
7.19, 5.27. HRMS (TOF ES+): Calcd for C31H52N2O5SSiNa






To a solution of ketone W20-2 (27 mg, 0.046 mmol) in THF (0.5 ml) at -78 °C was added L-




aq. NH4Cl (15 ml) and extracted with MTBE (2 x 15 ml). The combined organic extracts were 
dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica(4:1 to 1:1 hexanes:ethyl acetate) afforded W2 (28 mg, 98%) as a 10:1 
(NMR) mixture of stereoisomers. 
 
IR (ATR) 3212, 3996, 2875, 1713, 1455, 1242, 1196, 1127, 1085, 1005, 964, 739. 1H NMR (500 
MHz, CDCl3): δ 7.07 (s, 1H), 6.34 (m, 1H), 6.04 (m, 1H), 5.86 (m, 3H), 5.61 (q, J = 7.8 Hz, 1H), 
5.18 (dt, J = 1.5, 10.4 Hz, 1H), 4.75 (bs, 1H), 4.65 (m, 1H), 4.61 (bs, 1H), 3.36 (d, J = 9.8 Hz, 
1H), 3.14 (d, J = 2.9 Hz, 3H), 2.81 (d, J = 4.7 Hz, 3H), 2.44 (bs, HOH), 1.96-1.40 (m, 4H), 1.59 
(s, 3H), 1.24 (s, 3H), 0.96 (m, 15H), 0.59 (m, 6H). 13C NMR (125 MHz, CDCl3): δ 171.33, 
156.20, 141.89, 134.90, 129.67, 129.66, 127.87, 114.64, 113.84, 88.41, 71.73, 55.85, 49.67, 
44.72, 44.01, 41.93, 29.91, 27.84, 27.19, 24.81, 23.24, 22.22, 16.83, 14.34, 10.87, 8.93, 7.21, 
5.27. . HRMS (TOF ES+): Calcd for C31H54N2O5SSiNa




Method 1. Acid E1 (20 mg, 0.049 mmol) and alcohol W2 (16 mg, 0.027 mmol) were added to a 




nitrogen. To this mixture was added toluene (2.7 mL) and the reaction was cooled to -78oC. Et3N 
(45 µl, 0.324 mmol) was then added, followed by addition of DMAP (82 mg, 0.675 mmol).  
2,4,6-TCBC (48 µl, 0.305 mmol) was then added, and the reaction was warmed to r.t. and stirred 
overnight. The reaction was quenched with aq. NaHCO3 (5 ml) and extracted with EtOAc (2 x 3 
ml). The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography on silica (4:1 to 1:2 hexanes:ethyl acetate) afforded 
ester WE2 (16 mg, 60%) as an oil.   
 
Method 2. 4Å molecular sieves were flame dried under vacuum and alcohol # (17.5 mg, 0.0295 
mmol) was added to this same reaction tube in DCM (0.5 ml) and the mixture was stirred for 15 
min at rt. BOP (39 mg, 0.0885 mmol), DMAP (11 mg, 0.0885 mmol) and acid # (13.2 mg, 0.0325 
mmol) (added with 0.6 ml DCM) were then added sequentially. The resulting mixture was stirred 
at r.t. overnight. The reaction was quenched with brine (5 ml) and extracted with DCM (2 x 3 ml). 
The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography on silica (4:1 to 1:2 hexanes:ethyl acetate) afforded 
ester # (10 mg, 34%) as an oil.   
 
1H NMR (500 MHz, CDCl3): δ 7.06 (s, 1H), 6.67 (dd, J = 11, 17.6 Hz, 1H), 6.23 (m, 2H), 6.05 
(m, 1H), 5.84 (m, 3H), 5.55 (dd, J = 8.6, 14.8 Hz, 1H), 5.17 (dd, J = 6.5, 17.3 Hz, 1H), 5.10-5.00 
(m,3H), 4.75 (bs, 1H), 4.65 (d, J = 5.4 Hz, 1H), 4.08 (m, 1H), 3.34 (dd, J = 2.9, 10.2 Hz, 1H), 
3.13 (d, J = 12.2 Hz, 1H), 3.01 (m, 1H), 2.82 (d, J = 4.6 Hz, 3H), 2.31 (m, 2H), 2.01-1.51 (m, 
11H), 1.84 (d, J = 1.1 Hz, 3H), 1.74 (s, 3H), 1.55 (s, 6H), 1.25 (s, 6H), 0.99-0.81 (m, 27H), 0.59 




156.26, 154.55, 142.02, 136.03, 134.81, 134.34, 133.38, 132.41, 132.34, 130.72, 129.83, 128.59, 
127.28, 113.95, 113.76, 88.54, 73.14, 71.90, 71.88, 55.93, 55.82, 44.81, 42.07, 41.82, 40.75, 
39.27, 34.18, 30.04, 27.99, 26.17, 24.97, 24.86, 23.35, 22.46, 19.70, 18.49, 17.21, 17.18, 15.96, 
10.90, 9.03, 7.33, 5.41, -3.98, -4.55. 
Alcohol WE3 
 
To a solution of WE2 (15 mg, 0.0153mmol) in THF (2 ml) at 0 oC, HF-pyr (70%, 50 µl) was 
added. The resulting solution was kept at 4oC for 20h. The reaction was quenched with aq. 
NaHCO3 (5 ml) and extracted with EtOAc (2 x 5 ml). The combined organic extracts were dried 
over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography 
on silica (4:1 to 1:1 hexanes:ethyl acetate) afforded the intermediate secondary alcohol WE3 (8.7 
mg, 65%) as an oil. 
 
1H NMR (300 MHz, CDCl3): δ 7.05 (s, 1H), 6.67 (dd, J = 10.7, 17.2 Hz, , 1H), 6.22 (m, 1H), 
6.05 (m, 1H), 5.97-5.77 (m, 3H), 5.59 (dd, J = 1.9, 5.8 Hz, 1H), 5.54 (d, J = 8.4 Hz, 1H), 5.35-




Hz, 3H), 3.02 (m, 1H), 2.81 (d, J = 4.8 Hz, 3H), 2.29 (m, 2H), 2.09-1.51 (m, 23H), 1.24 (s, 3H), 
0.99-0.79 (m, 18H), 0.67 (t, J = 7.6 Hz, 3H), -0.031 (s, 3H), -0.064 (s, 3H).  
β -acyloxysulfone M3 
 
To a solution of methyl phenyl sulfone (3.75 g, 24 mmol) in THF (100 mL) at -78oC was added 
lithium bis(trimethylsilyl)amide (1.0M in THF, 24 mL) and resulting mixture was stirred at for 15 
min. The solution was warmed to 0oC for 10 min, and then cooled back to -78oC before adding 5-
hexanal (1.96 g, 20 mmol). The resulting mixture was warmed to r.t. for 5h followed by cooling 
to -78oC and addition of acetyl chloride (1.43 ml, 20 mmol). The mixture was allowed to warm to 
r.t. and stirred overnight. The reaction was quenched with aqueous NH4Cl (150 ml) and extracted 
with MTBE (2 x 50 ml). The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by flash column chromatography on silica (4:1 hexanes:ethyl 
acetate) afforded β-acyloxysulfone M3 (5.4 g, 97%) as a clear orange oil.  
 
IR (ATR) 2928, 1739, 1640, 1585, 1447, 1305, 1232, 1146, 1085, 1025, 916, 744, 688, 537. 1H 
NMR (500 MHz, CDCl3): δ 7.90 (dd, J = 1.2, 8.4 Hz, 2H), 7.68 (tt, J = 1.3, 6.7, 14.8 Hz, 1H), 
7.58 (m, 2H), 5.72 (ddd, J = 6.75, 10.2, 17.0 Hz, 1H), 5.25 (m, 1H), 4.96 (m, 2H), 3.46 (dd, J = 
8.1, 14.8 Hz, 1H), 3.26 (dd, J = 3.4, 14.8 Hz, 1H), 2.02 (m, 2H), 1.79 (s, 3H), 1.65 (m, 2H), 1.36 
(m, 2H). 13C NMR (125 MHz, CDCl3): δ 170.09, 137.94, 134.05, 129.53, 128.43, 115.49, 68.12, 
59.45, 33.76, 33.29, 24.14, 20.94. HRMS (TOF ES+) Calcd for C15H20O4SNa
+ (M+Na)+: 





β-acyloxysulfone dimer M4 
 
 A solution of β-acyloxysulfone M3(1.0 g, 3.37 mmol) was added in toluene (60 mL) at r.t.. The 
mixture degassed and then warmed to 60oC, Grubbs 2nd Generation catalyst (143 mg, 5 mol %) 
was added, and the reaction mixture was stirred for 20h before concentrating in vacuo. 
Purification by flash column chromatography on silica (1:1 hexanes:ethyl acetate to 100% ethyl 
acetate) afforded β-acyloxysulfone M4 (660 mg, 70%) as an oil.  
 
IR (ATR) 2928, 1739, 1640, 1447, 1373, 1305, 1231, 1145, 1086, 1025, 999, 915, 744, 688. 1H 
NMR (300 MHz, CDCl3): δ 7.92 (m, 4H), 7.66 (tt, J= 1.2, 6.1 Hz, 2H), 7.57 (m, 4H), 5.32-5.17 
(m, 4H), 3.47 (d, J = 7.9 Hz, 1H), 3.42 (d, J = 7.9 Hz, 1H), 3.28 (d, J = 3.4 Hz, 1H), 3.23 (d, J = 
3.4 Hz, 1H), 1.92 (m, 4H), 1.77 (s, 6H), 1.61 (m, 4H), 1.28 (m, 4H). 13C NMR (75 MHz, CDCl3): 
δ 169.85, 139.51, 133.80, 133.68, 130.09, 129.36, 129.29, 128.16, 127.34, 67.97, 59.22, 59.11, 
44.48, 33.75, 33.52, 33.48, 31.84, 31.78, 24.74, 20.71. HRMS (TOF ES+) Calcd for for 
C28H36O8S2Na












A solution of β-acyloxysulfone M4 (73 mg, 0.129 mmol) and known tert-butyldimethyl(oct-1-en-
3-yloxy)silane (6 mg .026 mmol) were added in toluene (1 mL) at rt.. The mixture was degassed 
and then warmed to 60oC, Grubbs 2nd Generation catalyst (5 mg, 20 mol %) was added, and the 
reaction mixture was stirred for 20h before concentrating in vacuo. Purification by flash column 
chromatography on silica (4:1 to 1:1 hexanes:ethyl acetate to 100% ethyl acetate) afforded β-





MeOH (784 µl) was added to a dry mixture of sodium mercury amalgam (115 mg, 0.250 mmol) 
and NaH2PO4 (41 mg, 0.292 mmol), followed by the addition of β-acyloxysulfone M5 (20 mg, 
.0392 mmol)) in THF (196 µl). The resulting mixture was stirred for 30 min at r.t. before filtering 
through cotton into aqueous brine (10 ml) and extracting with MTBE (2 x 5 ml). The combined 
organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash 
column chromatography on silica (10:1 hexanes:ethyl acetate) afforded compound M1 (7 mg, 58 





IR (ATR): 2926, 2855, 1252, 1077, 965, 834, 809, 773. 1H NMR (300 MHz, CDCl3): δ 5.81 (ddd, 
J = 6.5, 10.1, 16.9 Hz, 1H), 5.43 (m, 2H), 4.98 (m, 2H), 4.01 (q, J = 6.2 Hz, 1H), 2.04 (m, 4H), 
1.53-1.16 (m, 10H), 0.89 (m, 12H), 0.035 (s, 3H), 0.017 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 
138.78, 134.16, 129.72, 114.45, 73.78, 38.46, 33.21, 31.79, 31.52, 29.69, 28.55, 25.92, 25.07, 






To a degassed solution of β-acyloxysulfone M4 (500 mg, 1.79 mmol) and crotonaldehyde (1.5 
ml, 17.9 mmol) in toluene (18 ml) at 60oC was added Grubbs’ Second Generation catalyst (38 
mg, 0.045 mmol) and the resulting mixture was stirred for 6h before concentrating in vacuo. 
Purification on silica gel (Teledyne Isco CombiflashRf1000 with a gradient elution of 1:1 to 1:2 
to 100% hexanes:ethyl acetate, 10 ml fractions, 18 ml/min flow rate, solid sample loading) 
afforded aldehyde M13 (548 mg, 94%) as a clear orange oil.  
 
1H NMR (300 MHz, CDCl3): δ 9.47 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 7.8 Hz, 2H), 7.65 (m, 1H), 
7.57 (m, 2H), 6.76 (dt, J = 6.6, 15.6 Hz, 1H), 6.06 (m, 1H), 5.25 (m, 1H), 3.45 (dd, J = 7.7, 14.8 




13C NMR (75 MHz, CDCl3): δ 193.82, 169.88, 157.04, 139.36, 133.95, 133.37, 129.37, 128.11, 
67.53, 59.11, 33.55, 31.92, 23.05, 20.67, -1.61. 
 
Methyl ester M15 
O OAc












To a solution of thiazolidine thione M14 (404 mg, 1.52 mmol) in DCM (6.5 ml) at 0oC was added 
titanium tetrachloride (1.0 M, 1.6 ml) and the resulting orange solution was stirred at 0oC for 5 
min before adding triethyl amine (214 µl, 1.52 mmol) to give a wine red solution. The mixture 
was stirred for 10 min before cooling to -78oC and adding of N-methylpyrolidine (147 µl, 1.52 
mmol). The mixture was stirred for 20 min and then aldehyde M13 (542 mg, 1.67 mmol) was 
added as a solution in DCM (3 ml). The mixture was stirred at -78oC for 1hr followed by 
warming to 0oC for 1hr. The reaction was quenched with aqueous half-saturated NH4Cl (20 ml) 
and extracted with DCM (2 x 10 ml). The combined organic extracts were dried over MgSO4, 






To a solution of the crude alcohol obtained above in a DCM:MeOH solution (10:1, 15 ml) at 0oC 
was added imidazole (1.53 g, 22.5 mmol) and resulting mixture was allowed to slowly warm to 
r.t. while stirring for 15h. The reaction was quenched with aqueous half-saturated NH4Cl (30 ml) 
and extracted with DCM (2 x 15 ml). The combined organic extracts were dried over MgSO4, 
filtered, and concentrated in vacuo. Purification by flash column chromatography on silica (1:2 
hexanes:ethyl acetate to 100% ethyl acetate) afforded methyl ester M15 (297 mg, 93%) as an oil.  
 
1H NMR (300 MHz, CDCl3): δ 7.89 (m, 4H), 7.65 (m, 2H), 7.56 (m, 4H), 5.58 (M, 2H), 5.42 (dq, 
J = 1.1, 6.3 Hz, 1H), 5.36 (dq, J = 1.3, 6.4 Hz, 1H) 5.23 (m, 2H), 4.27 (s, 2H), 3.64 (s, 6H), 3.44 
(J = 8.0 Hz, 1H), 3.38 (d, J = 8.0 Hz, 1H), 3.26 (d, J = 3.6 Hz, 1H), 3.19 (d,J = 3.6 Hz, 1H), 2.68 
(m, 2H), 2.55 (m, 2H), 1.97 (q, J = 7.5 Hz, 4H), 1.74 (s, 3H), 1.73 (s , 3H), 1.56 (m, 4H), 1.29 (p, 
J = 7.6 Hz, 4H), 1.11 (m, 6H). 13C NMR (75 MHz, CDCl3): δ 175.58, 169.85, 139.41, 133.84, 
133.68, 131.99, 130.27, 130.23, 129.30, 128.12, 127.29, 73.04, 73.02, 67.78, 67.76, 59.13, 59.07, 
51.72, 45.01, 44.99, 44.43, 33.42, 33.36, 31.49, 31.43, 26.94, 24.07, 24.05, 20.66, 11.64, 11.62. 
HRMS (TOF ES+) Calcd for C2-H28O7SNa
+ (M+Na)+: 435.1454. Found: 435.1449. 
 
Methyl ester M15-1 
 
MeOH (9 ml) was added to a dry mixture of sodium mercury amalgam (1.9 g, 4.14 mmol) and 




mmol) in THF (3 ml). The resulting mixture was stirred for 30 min at r.t. before filtering through 
cotton into aqueous brine (20 ml) and extracting with MTBE (2 x 10 ml). The combined organic 
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (1:1 hexanes:ethyl acetate) afforded methyl ester M15-1 (87 mg, 72 %) 
as an oil.   
1H NMR (300 MHz, CDCl3): δ 5.77 (ddd, J = 6.7, 10.1, 17.0 Hz, 1H), 5.66 (m, 1H), 4.43 (ddt, J 
= 1.3, 6.6, 15.4 Hz, 1H), 4.94 (m, 2H), 4.29 (t, J = 5.6 Hz, 1H), 3.67 (s, 3H), 2.58 (m, 1H), 2.01 
(m, 4H), 1.45 (p, J = 7.7 Hz, 2H), 1.15 (dd, J = 0.8, 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 
175.68, 138.52, 133.17, 129.41, 144.06, 73.24, 51.71, 45.06, 33.09, 31.58, 28.28, 11.61.  
 




To a solution of methyl ester M15-1 (87 mg, 0.41 mmol) in DCM (4.1 ml) at 0oC was added 
imidazole (70 mg, 1.03 mmol) and tertbutyldimethylsilyl chloride (80.3 mg, 0.533 mmol) and the 
resulting mixture was allowed to warm to r.t. while stirring overnight. The reaction was quenched 
with water (10 ml) and extracted with DCM (2 x 5 ml). The combined organic extracts were dried 
over MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography 
on silica (4:1 hexanes:ethyl acetate) afforded methyl ester M16 (110 mg, 66%) as an oil.   
 
[α]D
20 = +2.08 (c 0.026, CH2Cl2). IR (ATR): 2954, 2926, 2855, 1640, 1595, 1360, 1249, 1085, 




Hz, 1H), 5.57 (dt, J = 6.7, 15.4 Hz, 1H), 5.41 (ddt, J = 1.0, 6.8, 15.4 Hz, 1H), 4.98 (m, 2H), 4.31 
(t, J = 6.3 Hz, 1H), 3.63 (s, 3H), 2.49 (dt, J = 6.9, 13 Hz, 1H), 2.03 (m, 4H), 1.44 (p, J = 7.7 Hz, 
2H), 1.14 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.013 (d, J = 0.8 Hz, 3H), -0.006 (d, J = 1.0, 3H). 13C 
NMR (75 MHz, CDCl3): δ 174.96, 138.61, 131.85, 131.54, 114.57, 74.93, 51.35, 47.14, 33.16, 





To a solution of diethyl phosponate (137 µl, .0.842 mmol) in THF (2 ml) at -78oC was added n-
butyl lithium (1.6 M in hexanes, 484 µl, 0.775 mmol) dropwise. The resulting mixture was stirred 
for 30 min before addition of methyl ester M16 (110 mg, 0.337 mmol) with THF (2 ml). The 
reaction was stirred for 30 min and subsequently quenched with half sat. aqueous NH4Cl (10 ml) 
and extracted with MTBE (2 x 5 ml). The combined organic extracts were dried over MgSO4, 
filtered, and concentrated in vacuo. Purification by flash column chromatography on silica (1:1 
hexanes:ethyl acetate) afforded phosphonate M17 (121 mg, 78%) as an oil.   
 
1H NMR (500 MHz, CDCl3): δ 5.75 (ddd, J = 1.2, 6.6, 17 Hz, 1H), 5.46 (m, 1H), 5.25 (ddd, J = 
1.3, 7.8, 15.4 Hz, 1H), 4.96 (dp, J = 2, 17 Hz, 1H), 4.91 (dq, J = 1, 10.2 Hz), 4.12-3.98 (m, 5H), 
3.56 (m, 1H), 3.27 (p, J = 6.7 Hz, 1H), 1.99 (m, 4H), 1.41 (p, J = 7.3 Hz, 2H), 1.28 (m, 6H), 1.21 




NMR (125 MHz, CDCl3): δ 208.69, 138.63, 132.85, 132.15, 131.67, 130.18, 114.80, 74.64, 
62.58, 53.77, 52.89, 49.01, 48.02, 46.29, 45.25, 33.37, 31.63, 29.35, 25.95, 24.06, 18.24, 16.56, 
13.94, 13.31, 11.66, 11.61, 10.47, 10.42, -3.79, -3.98, -4.66, -4.78. HRMS (TOF ES+) Calcd for 
C23H45O5PSiNa




Ba(OH)2·8H2O (83 mg, 0.263 mmol) was dried at 130
oC for 3 hours under vacuum prior to the 
addition of phosphonate M17 (121 mg, 0.263 mmol) in THF (1.55 ml). The resulting mixture was 
stirred at r.t. for 1.25h. Cinnamic aldehyde (100 µl, 0.789 mmol) was then added in 40:1 
THF:H2O (1.32 ml) and the reaction mixture stirred overnight. The reaction was quenched with 
aq. NaHCO3 (10 ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts were 
washed with 1M HCl (15 ml) and extracted with MTBE (2 x 5 ml), dried over MgSO4, filtered, 
and concentrated in vacuo. Purification by flash column chromatography on silica (20:1 
hexanes:ethyl acetate) afforded ketone M17-1 (100 mg, 87%) as an oil.   
 
1H NMR (300 MHz, CDCl3): δ 7.49 (d, J = 7.3 Hz, 2H), 7.37 (t, J = 7.2 Hz, 2H), 7.31 (t, J = 7.2 
Hz, 1H), 7.22-7.11 (m, 2H), 6.91 (d, J = 14.8 Hz, 1H), 5.75 (ddd, J = 6.6, 10, 16.9 Hz, 1H), 5.49 




4.90 (dq, J = 1.2, 10.1 Hz, 1H), 4.19 (t, J = 7.7 Hz, 1H), 3.43 (p, J = 6.8 Hz, 1H), 1.97 (m, 7H), 
1.39 (m, 2H), 1.16 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 0.063 (s, 3H), 0.019 (s, 3H). 13C NMR (75 
MHz, CDCl3): δ 204.36, 139.45, 138.66, 138.31, 136.73, 136.53, 131.94, 131.67, 128.85, 128.81, 
127.11, 124.69, 114.46, 76.38, 46.64, 33.10, 31.47, 28.33, 25.88, 18.19, 15.12, 12.04, -3.98, -
4.76. HRMS (TOF ES+) Calcd for C28H42O2SiNa




To a solution of ketone M17-1 (50 mg, 0.114 mmol) in MeOH (1.5 ml) at 0oC under air was 
added NaBH4 (17 mg, 0.456 mmol). The resulting mixture was stirred for 1h. The reaction was 
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 5 ml). The combined organic 
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (20:1 hexanes:ethyl acetate) afforded alcohol M17-2 (40 mg, 79%) as 
an oil.   
 
[α]D
20 = +36 (c 0.03, CH2Cl2). IR (ATR): 2926, 2584, 1741, 1381, 1249, 1085, 1035, 962, 834, 
774, 690. 1H NMR (300 MHz, CDCl3): δ 7.41 (d, 7.7 Hz, 2H), 7.30 (t, J = 7.2 Hz, 2H), 7.19 (m, 
1H), 7.02 (dd, J = 10.9, 15.5 Hz, 1H), 6.51 (d, J = 15.5 Hz, 1H), 6.14 (d, J = 11 Hz, 1H), 5.82 
(ddd, J = 6.6, 10.2, 16.8 Hz, 1H), 5.61 (m, 2H), 5.01 (m, 2H), 4.31 (m, 2H), 4.01 (d, J = 9.4 Hz, 




7.1 Hz, 3H), 0.103 (s, 3H), 0.059 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 139.57, 138.61, 137.76, 
132.93, 131.95, 129.08, 128.55, 127.47, 127.23, 126.24, 124.96, 114.67, 80.70, 78.00, 41.37, 
33.24, 31.67, 28.48, 25.79, 18.05, 13.10, 11.75, -0.0097, -4.18, -5.11. 
 




To a solution of alcohol M17-2 (60 mg, 0.136 mmol) in THF (2 ml) at -78oC was added lithium 
bis(trimethylsilyl)amide (1.0 M in THF, 204 µl). The mixture was stirred for 30 min. Methyl 
iodide (42 µl, 0.68 mmol) was then added and the reaction mixture was warmed to r.t. while 
stirred overnight. The reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE 
(2 x 3 ml). The combined organic extracts were dried over MgSO4, filtered, and concentrated in 
vacuo. Purification by flash column chromatography on silica (20:1 hexanes:ethyl acetate) 
afforded M6 (51 mg, 68%) as an oil.    
[α]D
20 = +1.25 (c 0.024, CH2Cl2). IR (ATR): 2926, 2855, 1641, 1496, 1461, 1381, 1321, 1249, 
1085, 1035, 963, 834, 773, 690. 1H NMR (300 MHz, CDCl3): δ 7.42 (d, J = 7.5 Hz, 2H), 7.32 (t, 
J = 7.4 Hz, 2H), 7.21 (t, J = 7 Hz, 1H), 7.04 (dd, J = 10.9, 15.5 Hz, 1H), 6.56 (d, J = 15.5 Hz, 
1H), 6.12 (d, J = 11.2 Hz, 1H), 5.81 (ddd, J = 6.7, 10.2, 16.9 Hz, 1H), 5.53 (m, 2H), 4.97 (m, 




1.62 (m, 1H), 1.47 (m, 2H), 0.94 (s, 9H), 0.66 (d, J = 6.9 Hz, 3H), 0.069 (s, 3H), 0.015 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ 138.81, 137.64, 137.36, 133.25, 132.09, 130.02, 128.59, 127.36, 
127.25, 126.26, 124.53, 114.45, 88.39, 71.07, 55.75, 42.37, 33.28, 31.67, 28.59, 26.02, 18.25, 
11.00, 8.81, 0.49, -3.72, -5.11. HRMS (TOF ES+) Calcd for C29H46O2SiNa







To a solution of methyl ester M16 (50 mg, 0.153 mmol) in DCM (2 ml) at -78oC was added 
DIBAl-H (70 µl, 0.337 mmol). The resulting mixture was warmed to 0oC and stirred for 45 min. 
The reaction was quenched by diluting with ethyl acetate (2 ml) into Rochelle’s salt (2M, 4 ml). 
The mixture was stirred for 45 min before being transferred to a separatory funnel and extracted 
with ethyl acetate (2 x 5 ml). The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by flash column chromatography on silica (10:1 to 4:1 
hexanes:ethyl acetate) afforded # (30 mg, 66%) as an oil.    
 
1H NMR (300 MHz, CDCl3): δ 5.80 (ddd, J = 6.8, 10.1, 17.0 Hz, 1H), 5.54 (m, 2H), 4.98 (m, 
2H), 4.18 (dd, J = 4.2, 6.5 Hz, 1H), 3.65 (td, J = 1.4, 10.3 Hz, 1H), 3.47 (m, 1H), 2.96 (d, J = 4.6 
Hz, 1H), 2.03 (m, 5H), 1.47 (p, J = 7.8 Hz, 1H), 0.87 (s, 9H), 0.77 (d, J = 7.1 Hz, 3H), 0.063 (s, 




33.20, 31.63, 28.50, 25.79, 18.06, 12.55, -1.61, -4.26, -5.11. HRMS (TOF ES+) Calcd for 
C17H34O2SiNa
+ (M+Na)+: 321.2226. Found: 321.2222.  
 
Methyl ether M20 
 
 
To a solution of alcohol # (21 mg, 0.0704 mmol) in THF (1.5 ml) at -78oC was added lithium 
bis(trimethylsilyl)amide (1.0 M in THF, 106 µl). The mixture was stirred for 30 min. Methyl 
triflate (12 µl, 0.106 mmol) was then added and the reaction mixture was stirred for 1h. The 
reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 3 ml). The 
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography on silica (20:1 hexanes:ethyl acetate) afforded # (15 
mg, 68%) as an oil.    
 
1H NMR (300 MHz, CDCl3): δ 5.80 (m, 1H), 5.53 (m, 1H), 4.97 (m, 2H), 4.13 (m, 1H), 3.38-3.08 
(m, 5H), 2.03 (m, 4H), 1.74 (m, 1H), 1.55 (m, 2H), 1.25 (m, 3H), 0.87 (m, 9H), 0.017 (m, 3H), -
0.013 (m, 3H).  13C NMR (75 MHz, CDCl3): δ 138.97, 132.59, 130.75, 114.69, 75.31, 73.37, 











Ba(OH)2·8H2O (178 mg, 0.56 mmol) was dried at 130
oC for 3 hours under vacuum prior to the 
addition of phosphonate W3 (174 mg, 0.47 mmol) in THF (2.8 ml). The resulting mixture was 
stirred at r.t. for 1.25h. Aldehyde # (300 mg, 2.6 mmol) was then added in 40:1 THF:H2O (2.4 
ml) and the reaction mixture stirred overnight. The reaction was quenched with aq. NaHCO3 (10 
ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts were washed with 1M 
HCl (15 ml) and extracted with MTBE (2 x 5 ml), dried over MgSO4, filtered, and concentrated 
in vacuo. Purification by flash column chromatography on silica (20:1 to 10:1 hexanes:ethyl 






To a solution of ketone W22-1 (70 mg, 0.248 mmol) in MeOH (1.3 ml) at 0oC under air was 
added NaBH4 (37 mg, 0.992 mmol). The resulting mixture was stirred for 1h. The reaction was 




extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (10:1 hexanes:ethyl acetate) afforded alcohol W22-2 (65 mg, 92%) as 
an oil.   
 




To a solution of alcohol W22-1 (65 mg, 0.228 mmol) in THF (1 ml) at -78oC was added lithium 
bis(trimethylsilyl)amide (1.0 M in THF, 343 µl). The mixture was stirred for 30 min. Methyl 
triflate (40 µl, 0.343 mmol) was then added and the reaction mixture was stirred for 1h. The 
reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 3 ml). The 
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography on silica (20:1 hexanes:ethyl acetate) afforded 
methyl ether W22-3 (45 mg, 66%) as an oil.    
 
1H NMR (500 MHz, CDCl3): δ 5.23 (ddd, J = 5.6, 10.5, 17.2 Hz, 1H), 5.39 (qd, J = 1.3, 6.5, 13.3 
Hz, 1H), 5.17 (dt, J = 1.7, 17.2 Hz, 1H), 5.03 (dt, J = 1.6, 10.5 Hz, 1H), 4.63 (dq, J = 1.5, 5.6 Hz, 
1H), 3.32 (d, J = 10 Hz, 1H), 3.12 (s, 3H), 1.64 (dd, J = 1.0, 6.7 Hz, 3H), 1.56 (m, 1H), 1.46 (t, J 
= 1.1 Hz, 3H), 0.92 (s, 9H), 0.60 (d, J = 6.9 Hz, 3H), 0.048 (s, 3H), 0.0029 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ 141.73, 141.28, 133.69, 124.74, 122.89, 114.04, 113.61, 88.35, 87.81, 




3.61, -3.92, -4.97, -5.24. HRMS (TOF CI+) Calcd for C16H35O2Si






To a solution of methyl ether W22-3 (45 mg, 0.113 mmol) in THF (0.75 ml) at 0 oC, HF-pyr 
(70%, 195 µl) was added. The resulting solution was kept at r.t. for 20h. The reaction was 
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 10 ml). The combined organic 
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (10:1 to 4:1 hexanes:ethyl acetate) afforded the secondary alcohol W22 
(22 mg, 98%) as an oil.  
 
1H NMR (500 MHz, CDCl3): δ 5.92 (dq, J =  1.2, 5.2, 5.4 Hz, 1H), 5.41 (qd, J =  1.3, 5.3 Hz, 
1H), 5.29 (dt, J = 1.8, 17.2 Hz, 1H), 5.20 (dt, J = 1.8, 10.6 Hz, 1H), 4.19 (m, 1H), 3.82 (d, J = 
8.5 Hz, 1H), 3.38 (d, J = 939 Hz, 1H), 3.13 (s, 3H), 2.06 (m, 1H), 1.64 (dd, J = 1.07, 6.9 Hz, 3H), 
1.63 (s, 3H), 1.52 (m, 3H). 13C NMR (125 MHz, CDCl3): δ 138.46, 133.03, 125.09, 115.31, 
91.09, 76.07, 55.51, 39.73, 13.33, 13.22, 10.26. HRMS (TOF CI+) Calcd for C11H20O2SiNa
+ 










W22 (11 mg, 0.0596 mmol) was added in DCM (6 ml). The mixture underwent two freeze-pump-
thaw cycles. Once r.t. was reached, Grubbs’ Second Generation catalyst (2.5 mg, 0.003 mmol) 
was added and the resulting mixture was stirred at r.t. overnight. The reaction mixture was 
transferred to a round bottom flask and concentrated in vacuo. Purification on silica gel (1:1 to 
1:2 hexanes:ethyl acetate to 100% ethyl acetate) afforded cyclopentene R2 (10 mg, 91%) as an 
oil.  
 
IR (ATR) 3360, 2925, 1653, 1558, 1456, 1375, 1192, 1090, 1019, 968, 897. 1H NMR (500 MHz, 
CDCl3): δ 5.57 (s, 1H), 4.41 (d, J = 1.6 Hz, 1H), 4.17 (d, J = 6.1 Hz, 1H). 3.38 (s, 3H), 2.16 (m, 
1H), 1.78 (s, 3H),1.59 (s, 1H) 1.06 (d, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 144.79, 
130.81, 88.51, 82.72, 58.81, 46.93, 14.98, 12.28. HRMS (TOF CI+) Calcd for C8H13O2
- (M-H)-: 















Ba(OH)2·8H2O (139 mg, 0.441 mmol) was dried at 130
oC for 3 hours under vacuum prior to the 
addition of phosphonate W3 (173 mg, 0.441 mmol) in THF (2.5 ml). The resulting mixture was 
stirred at r.t. for 1.25h. Cinnamic aldehyde (166 µl, 1.322 mmol) was then added in 40:1 
THF:H2O (2.2 ml) and the reaction mixture stirred overnight. The reaction was quenched with aq. 
NaHCO3 (10 ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts were 
washed with 1M HCl (15 ml) and extracted with MTBE (2 x 5 ml), dried over MgSO4, filtered, 
and concentrated in vacuo. Purification by flash column chromatography on silica (4:1 
hexanes:ethyl acetate) afforded ketone M7-1 (155mg, 95%) as an oil.   
 
IR (ATR) 2955, 2928, 2855, 1652, 1617, 1472, 1362, 1251, 1203, 1073, 1025, 965, 835, 776, 
750, 689. 1H NMR (500 MHz, CDCl3): δ 7.49 (d, J = 8.1 Hz, 2H), 7.35 (m, 3H), 7.18 (s, 1H), 
7.11 (dd, J = 1.7, 10.2 Hz, 1H), 6.91 (d, J = 13.6 Hz, 1H), 5.76 (ddd, J = 1.8, 6.6, 17.2 Hz, 1H), 
5.14 (dt, J = 1.8, 17.2 Hz, 1H), 5.01 (dt, J = 1.9, 10.5 Hz, 1H), 4.23 (t, J = 6.8 Hz, 1H), 3.43 (p, J 
= 6.8 Hz, 1H), 1.97 (s, 3H), 1.17 (dd, J = 1.6, 6.8 Hz, 3H), 0.91 (d, J = 1.9 Hz, 3H), 0.05 (s, 3H), 
0.01 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 204.09, 139.74, 139.71, 138.37, 136.53, 136.50, 










To a solution of ketone M7-1 (155 mg, 0.4182 mmol) in MeOH (2.1 ml) at 0oC under air was 
added NaBH4 (64 mg, 1.6729 mmol). The resulting mixture was stirred for 1h. The reaction was 
quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 5 ml). The combined organic 
extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (4:1 hexanes:ethyl acetate) afforded alcohol M7-2 (116 mg, 75%) as an 
oil.   
 
IR (ATR) 3420, 3955, 1462, 1404, 1252, 1142, 1081, 1024, 960, 890, 775, 690. 1H NMR (500 
MHz, CDCl3): δ 7.42 (d, J = 7.8 Hz, 2H), 7.31 (t, J = 7.9 Hz, 2H), 7.21 (tt, J = 1.7, 7.4 Hz, 1H), 
7.05 (dd, J = 11, 15 Hz, 1H), 6.53 (d, J = 15.6 Hz, 1H), 6.15 (d, J = 11 Hz, 1H), 5.97 (ddd, J = 
6.4, 10.5, 17 Hz, 1H), 5.24 (m, 2H), 4.39 (m, 1H), 4.07 (d, J = 1.7, 1H), 4.01 (dd, J = 1.3, 9.4 Hz, 
1H), 1.86 (d, J = 1.0 Hz, 3H), 0.95 (s, 9H), 0.70 (d, J = 7.1 Hz, 3H), 0.13 (s, 3H), 0.09 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 139.51, 137.82, 137.40, 137.39, 132.19, 128.68, 127.75, 126.37, 








Methyl ether M7 
 
 
To a solution of alcohol M7-2 (45 mg, 0.1208 mmol) in THF (1.2 ml) at -78oC was added lithium 
bis(trimethylsilyl)amide (1.0 M in THF, 181 µl). The mixture was stirred for 30 min. Methyl 
triflate (20 µl, 0.181 mmol) was then added and the reaction mixture was stirred for 1h. The 
reaction was quenched with aq. NaHCO3 (5 ml) and extracted with MTBE (2 x 3 ml). The 
combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography on silica (20:1 to 10:1 hexanes:ethyl acetate) 
afforded M7 (44 mg, 95%) as an oil.    
 
[α]D
20 = +204 (c 0.025, CH2Cl2). IR (ATR) 2954, 2927, 2855, 1596, 1471, 1250, 1083, 876, 774, 
690, 746. 1H NMR (500 MHz, CDCl3): δ 7.43 (d. J = 8.1 Hz, 2H) 7.32 (m, 2H), 7.22 (tt, J = 1.2, 
6.8 Hz, 1H), 7.04 (dd, J = 4.7, 11, 15.4 Hz, 1H), 6.57 (d, J = 15.3 Hz, 1H), 6.12 (d, J = 11 Hz, 
1H), 5.84 (ddd, J = 5.6, 10.4, 17.2 Hz, 1H), 5.19 (dt, J = 1.7, 17.2 Hz, 1H), 5.06 (dt, J = 1.5, 10.6 
Hz, 1H), 4.66 (dq, J = 1.5, 5.7 Hz, 1H), 3.45 (d, J = 9.9 Hz, 1H), 3.18 (s, 3H), 1.74 (d, J = 1.2, 
3H), 1.63 (m, 1H), 0.95 (s, 9H), 0.64 (d, J = 7.0 Hz, 3H), 0.08 (s, 3H), 0.03 (s, 3H). ). 13C NMR 
(125 MHz, CDCl3): δ 141.67, 137.78, 137.38, 132.38, 130.07, 128.79, 127.56, 126.45, 124.65, 
114.02, 88.42, 71.41, 55.89, 41.99, 26.19, 18.46, 11.14, 8.86, -3.74, -5.02. HRMS (TOF ES+) 
Calcd for C24H38O2SiNa







To a solution of methyl ether M7 (20 mg, 0.052 mmol) in THF (1.5 ml) at 0 oC, HF-pyr (70%, 
390 µl) was added. The resulting solution was kept at r.t. for 20h. The reaction was quenched 
with aq. NaHCO3 (10 ml) and extracted with MTBE (2 x 5 ml). The combined organic extracts 
were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash column 
chromatography on silica (4:1 hexanes:ethyl acetate) afforded the secondary alcohol M8 (6 mg, 
43%) as an oil.  
 
1H NMR (300 MHz, CDCl3): δ7.42 (d, J = 2 Hz, 2H), 7.32 (t, J = 7.2 Hz, 2H), 7.22 (tt, J = 2.3, 
8.2 Hz, 1H), 7.02 (dd, J = 10.95, 15.6 Hz, 1H), 6.55 (d, J = 15.6 Hz, 1H), 6.14 (dt, J = 0.5, 11 Hz, 
1H), 5.94 (ddd, J = 5.1, 10.4, 17.1 Hz, 1H), 5.33 (dt, J = 1.8, 17.2 Hz, 1H), 5.23 (dt, J = 1.7, 10.5 
Hz, 1H), 4.25 (m, 1H), 3.52 (d, J = 9.6 Hz, 1H), 3.12 (s, 3H), 2.10 (m, 1H), 1.78 (d, J = 1.2 Hz, 
3H), 0.74 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 138.40, 135.90, 133.01, 129.89, 










Methyl ether NW 
 
 
As an alternative to the previously reported methylation of alcohol W13, Meerwien’s salt can be 
used as a methylating agent. A solution of alcohol W13 (100 mg, 0.203 mmol) in DCM (4 ml) 
was transferred via cannula to a reaction tube containing Meerwein’s salt (90 mg, 0.611 mmol) 
and proton sponge (175 mg, 0.815 mmol). The resulting mixture was stirred at r.t. for 2h. The 
reaction was quenched with ice cold water (5 ml), then transferred to a separatory funnel 
containing aq. NaHCO3 (10 ml) and was extracted with MTBE (2 x 5 ml). The combined organic 
extracts were washed with brine, and extracted again with MTBE (2 x 5 ml). The combined 
organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash 
column chromatography on silica (20:1 hexanes:ethyl acetate) afforded methyl ether NW (56 mg, 
55%) as an oil. 
For characterization information, see: A.B. Tran, G.C. Melly, G.W. O’Neil Org. Biomol. Chem., 
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